



Clinical trial results:

Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - EXTended Criteria Donors (BENEFIT-EXT)

Summary

| | |
|--------------------------|-------------------------------|
| EudraCT number | 2004-002974-48 |
| Trial protocol | GB HU AT BE SE DE CZ IT ES PT |
| Global end of trial date | 30 September 2014 |

Results information

| | |
|--------------------------------|------------------|
| Result version number | v1 (current) |
| This version publication date | 28 December 2016 |
| First version publication date | 28 December 2016 |

Trial information

Trial identification

| | |
|-----------------------|-----------|
| Sponsor protocol code | IM103-027 |
|-----------------------|-----------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT00114777 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | Bristol-Myers Squibb International Corporation |
| Sponsor organisation address | Chaussee de la Hulpe 185, Brussels, Belgium, 1170 |
| Public contact | Bristol-Myers Squibb Study Director, Bristol-Myers Squibb International Corporation, clinical.trials@bms.com |
| Scientific contact | Bristol-Myers Squibb Study Director, Bristol-Myers Squibb International Corporation, clinical.trials@bms.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|-------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 30 September 2014 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 30 September 2014 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The main objective of the study was to evaluate the effects of belatacept, relative to cyclosporin A, on the following:

1. Subject and graft survival by 12 months
2. Measured glomerular filtration (GFR) rate <60 mL/min/1.73 m² at Month 12 or a decrease in measured GFR ≥ 10 mL/min/1.73 m² from Month 3 to Month 12.

Assess the long term safety and tolerability of belatacept in subjects who have received a kidney transplant, completed the Short Term (36 months of treatment in the main study) and remain on study therapy for up to an additional 48 months.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization Good Clinical Practice Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy:

All subjects received induction with basiliximab and a background maintenance immunosuppressive regimen of mycophenolate mofetil and corticosteroids.

Evidence for comparator: -

| | |
|---|---------------|
| Actual start date of recruitment | 10 March 2005 |
| Long term follow-up planned | Yes |
| Long term follow-up rationale | Safety |
| Long term follow-up duration | 48 Months |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | Czech Republic: 12 |
| Country: Number of subjects enrolled | France: 106 |
| Country: Number of subjects enrolled | Germany: 49 |
| Country: Number of subjects enrolled | Hungary: 5 |
| Country: Number of subjects enrolled | Italy: 17 |
| Country: Number of subjects enrolled | Norway: 9 |
| Country: Number of subjects enrolled | Poland: 3 |
| Country: Number of subjects enrolled | South Africa: 1 |
| Country: Number of subjects enrolled | Spain: 55 |
| Country: Number of subjects enrolled | Sweden: 3 |
| Country: Number of subjects enrolled | United Kingdom: 3 |

| | |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | United States: 139 |
| Country: Number of subjects enrolled | Argentina: 64 |
| Country: Number of subjects enrolled | Austria: 10 |
| Country: Number of subjects enrolled | Australia: 2 |
| Country: Number of subjects enrolled | Belgium: 8 |
| Country: Number of subjects enrolled | Brazil: 95 |
| Country: Number of subjects enrolled | Canada: 13 |
| Country: Number of subjects enrolled | Chile: 1 |
| Worldwide total number of subjects | 595 |
| EEA total number of subjects | 280 |

Notes:

Subjects enrolled per age group

| | |
|---|-----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 416 |
| From 65 to 84 years | 179 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Subjects were enrolled at 79 sites; 28 in the United States, 9 in France, 6 in Brazil, 5 each in Germany, Argentina, and Spain, 4 in Canada, 3 in Italy, 2 each in Hungary, Austria, and Poland, 1 each in Belgium, Chile, Czech Republic, Norway, South Africa, Sweden, UK, and Australia.

Pre-assignment

Screening details:

A total of 595 subjects were enrolled; 578 were randomized: 13 subjects no longer met study criteria; 3 discontinued on sponsor's discretion; and 1 discontinued due to "other" reason.

Period 1

| | |
|------------------------------|---------------------------|
| Period 1 title | Randomization to Month 36 |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator |

Blinding implementation details:

During the first 36 months, study drugs (belatacept or cyclosporine A) were administered in an open-label fashion. The assigned dose regimen (MI or LI) of the belatacept-treated subjects was blinded both to the subjects and study personnel up to Month 36.

Arms

| | |
|------------------------------|--------------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Belatacept MI (Period 1) |

Arm description:

Subjects in more intensive (MI) regimen received belatacept 10 mg/kg intravenous solution on Days 1 and 5 during the first week, and then every other week through 3 months (Weeks 2, 4, 8, and 12) and then every 4 weeks through 6 months (Weeks 16, 20 and 24), followed by a maintenance dose of belatacept, 5 mg/kg intravenously every 4 weeks thereafter for up to 36 months.

| | |
|--|-----------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Belatacept |
| Investigational medicinal product code | BMS-224818 |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Belatacept 10-mg/kg intravenous solution over 30 minutes on Days 1 and 5 during the first week, and then every other week through 3 months (Weeks 2, 4, 8, and 12) and then every 4 weeks through 6 months (Weeks 16, 20 and 24), followed by a maintenance dose of belatacept, 5 mg/kg intravenously every 4 weeks thereafter for 36 months.

| | |
|------------------|--------------------------|
| Arm title | Belatacept LI (Period 1) |
|------------------|--------------------------|

Arm description:

Subjects in less intensive (LI) regimen received belatacept, 10 mg/kg intravenously on Day 1 and Day 5 during the first week, and then every other week for 4 weeks (Weeks 2 and 4), and then every 4 weeks for 2 months (Weeks 8 and 12), followed by a maintenance dose of belatacept, 5 mg/kg intravenously every 4 weeks thereafter for up to 36 months.

| | |
|--|-----------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Belatacept |
| Investigational medicinal product code | BMS-224818 |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Belatacept 10-mg/kg intravenous solution for over 30 minutes on n Day 1 and Day 5 during the first week, and then every other week for [4] weeks (Weeks 2 and 4), and then every 4 weeks for 2 months (Weeks 8 and 12), followed by a maintenance dose of belatacept, 5 mg/kg i.v. every 4 weeks thereafter for 36 months.

| | |
|------------------|--------------------------|
| Arm title | Cyclosporin A (Period 1) |
|------------------|--------------------------|

Arm description:

Subjects received an initial daily dose of 4 -10 mg/kg cyclosporin A capsules orally, in 2 divided doses, adjusted thereafter to maintain serum concentrations of 150-300 ng/mL during the first month. Subsequently, doses were adjusted to maintain a predefined range of trough serum concentrations of 100-250 ng/mL for up to 36 months.

| | |
|--|---------------|
| Arm type | Experimental |
| Investigational medicinal product name | Cyclosporin A |
| Investigational medicinal product code | |
| Other name | Neoral® |
| Pharmaceutical forms | Capsule |
| Routes of administration | Oral use |

Dosage and administration details:

Cyclosporine was initially administered at a daily dose of 4-10 mg/kg, orally as capsules. The dose was then adjusted to maintain trough whole blood concentrations of 150-300 ng/mL during the first month. Subsequently, doses were adjusted to maintain a predefined range of trough whole blood concentrations of 100-250 ng/mL for up to 36 months.

| Number of subjects in period 1^[1] | Belatacept MI (Period 1) | Belatacept LI (Period 1) | Cyclosporin A (Period 1) |
|---|--------------------------|--------------------------|--------------------------|
| Started | 184 | 175 | 184 |
| Received treatment | 183 | 174 | 179 |
| Completed | 109 | 114 | 100 |
| Not completed | 75 | 61 | 84 |
| Consent withdrawn by subject | 3 | 4 | 5 |
| Adverse event, non-fatal | 34 | 35 | 44 |
| Poor/non-Compliance | - | - | 1 |
| Death | 10 | 4 | 3 |
| Subject no longer meet study criteria | - | - | 2 |
| Other reasons | 9 | 3 | 12 |
| Lack of efficacy | 19 | 15 | 17 |

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial as of the 595 subjects enrolled only 578 subjects randomized and 543 were transplanted into the study. The 17 subjects which were not randomized for the following reasons: 13 no longer met study criteria, 3 discontinued on sponsor's discretion, and 1 discontinued for "other", a non-specified reason.

Period 2

| | |
|------------------------------|---------------------------------|
| Period 2 title | Long-Term Extension to Month 84 |
| Is this the baseline period? | No |
| Allocation method | Non-randomised - controlled |
| Blinding used | Not blinded |

Blinding implementation details:

The long-term extension was conducted as a fully open-label clinical study.

Arms

| | |
|------------------------------|--------------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Belatacept MI (Period 2) |

Arm description:

Subjects in more intensive (MI) regimen during long term extension continued to receive belatacept at a maintenance dose of 5 mg/kg intravenously every 4 weeks for up to 84 months.

| | |
|--|-----------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Belatacept |
| Investigational medicinal product code | BMS-224818 |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Belatacept 5 mg/kg intravenous solution over 30 minutes every 4 weeks for up to 84 months.

| | |
|------------------|--------------------------|
| Arm title | Belatacept LI (Period 2) |
|------------------|--------------------------|

Arm description:

Subjects in less intensive (LI) regimen during long term extension continued to receive belatacept at a maintenance dose of 5 mg/kg intravenously every 4 weeks for up to 84 months.

| | |
|--|-----------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Belatacept |
| Investigational medicinal product code | BMS-224818 |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Belatacept 5 mg/kg intravenous solution over 30 minutes every 4 weeks for up to 84 months.

| | |
|------------------|--------------------------|
| Arm title | Cyclosporin A (Period 2) |
|------------------|--------------------------|

Arm description:

Subjects during the long-term extension continued to receive doses that were adjusted to maintain a predefined range of trough serum concentrations of 100-250 ng/mL for up to 84 months.

| | |
|--|---------------|
| Arm type | Experimental |
| Investigational medicinal product name | Cyclosporin A |
| Investigational medicinal product code | |
| Other name | Neoral® |
| Pharmaceutical forms | Capsule |
| Routes of administration | Oral use |

Dosage and administration details:

Cyclosporine A doses were adjusted to maintain a predefined range of trough whole blood concentrations of 100-250 ng/mL for up to 84 months.

| Number of subjects in period 2^[2] | Belatacept MI (Period 2) | Belatacept LI (Period 2) | Cyclosporin A (Period 2) |
|---|---------------------------------|---------------------------------|---------------------------------|
| Started | 104 | 113 | 87 |
| Completed | 74 | 84 | 57 |
| Not completed | 30 | 29 | 30 |
| Consent withdrawn by subject | 2 | 1 | 6 |
| Adverse event, non-fatal | 15 | 14 | 7 |
| Poor/non-Compliance | 1 | 1 | 3 |
| Death | 8 | 13 | 7 |
| Subject no longer met study criteria | 1 | - | - |
| Other reasons | 2 | - | 3 |
| Lost to follow-up | - | - | 2 |
| Subject no longer meets study criteria | - | - | 1 |
| Lack of efficacy | 1 | - | 1 |

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Not all participants chose to enter long-term extension phase.

Baseline characteristics

Reporting groups

| | |
|-----------------------|--------------------------|
| Reporting group title | Belatacept MI (Period 1) |
|-----------------------|--------------------------|

Reporting group description:

Subjects in more intensive (MI) regimen received belatacept 10 mg/kg intravenous solution on Days 1 and 5 during the first week, and then every other week through 3 months (Weeks 2, 4, 8, and 12) and then every 4 weeks through 6 months (Weeks 16, 20 and 24), followed by a maintenance dose of belatacept, 5 mg/kg intravenously every 4 weeks thereafter for up to 36 months.

| | |
|-----------------------|--------------------------|
| Reporting group title | Belatacept LI (Period 1) |
|-----------------------|--------------------------|

Reporting group description:

Subjects in less intensive (LI) regimen received belatacept, 10 mg/kg intravenously on Day 1 and Day 5 during the first week, and then every other week for 4 weeks (Weeks 2 and 4), and then every 4 weeks for 2 months (Weeks 8 and 12), followed by a maintenance dose of belatacept, 5 mg/kg intravenously every 4 weeks thereafter for up to 36 months.

| | |
|-----------------------|--------------------------|
| Reporting group title | Cyclosporin A (Period 1) |
|-----------------------|--------------------------|

Reporting group description:

Subjects received an initial daily dose of 4 -10 mg/kg cyclosporin A capsules orally, in 2 divided doses, adjusted thereafter to maintain serum concentrations of 150-300 ng/mL during the first month. Subsequently, doses were adjusted to maintain a predefined range of trough serum concentrations of 100-250 ng/mL for up to 36 months.

| Reporting group values | Belatacept MI (Period 1) | Belatacept LI (Period 1) | Cyclosporin A (Period 1) |
|------------------------|--------------------------|--------------------------|--------------------------|
| Number of subjects | 184 | 175 | 184 |
| Age categorical | | | |
| Units: Subjects | | | |
| 18 years to 45 years | 32 | 35 | 34 |
| 46 years to 65 years | 100 | 97 | 108 |
| more than 65 years | 52 | 43 | 42 |
| Age continuous | | | |
| Units: years | | | |
| arithmetic mean | 56.7 | 56.1 | 55.7 |
| standard deviation | ± 12.6 | ± 12.4 | ± 12.2 |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 65 | 46 | 68 |
| Male | 119 | 129 | 116 |

| Reporting group values | Total | | |
|------------------------|-------|--|--|
| Number of subjects | 543 | | |
| Age categorical | | | |
| Units: Subjects | | | |
| 18 years to 45 years | 101 | | |
| 46 years to 65 years | 305 | | |
| more than 65 years | 137 | | |
| Age continuous | | | |
| Units: years | | | |
| arithmetic mean | - | | |
| standard deviation | - | | |

| | | | |
|--------------------|-----|--|--|
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 179 | | |
| Male | 364 | | |

End points

End points reporting groups

| | |
|-----------------------|--------------------------|
| Reporting group title | Belatacept MI (Period 1) |
|-----------------------|--------------------------|

Reporting group description:

Subjects in more intensive (MI) regimen received belatacept 10 mg/kg intravenous solution on Days 1 and 5 during the first week, and then every other week through 3 months (Weeks 2, 4, 8, and 12) and then every 4 weeks through 6 months (Weeks 16, 20 and 24), followed by a maintenance dose of belatacept, 5 mg/kg intravenously every 4 weeks thereafter for up to 36 months.

| | |
|-----------------------|--------------------------|
| Reporting group title | Belatacept LI (Period 1) |
|-----------------------|--------------------------|

Reporting group description:

Subjects in less intensive (LI) regimen received belatacept, 10 mg/kg intravenously on Day 1 and Day 5 during the first week, and then every other week for 4 weeks (Weeks 2 and 4), and then every 4 weeks for 2 months (Weeks 8 and 12), followed by a maintenance dose of belatacept, 5 mg/kg intravenously every 4 weeks thereafter for up to 36 months.

| | |
|-----------------------|--------------------------|
| Reporting group title | Cyclosporin A (Period 1) |
|-----------------------|--------------------------|

Reporting group description:

Subjects received an initial daily dose of 4 -10 mg/kg cyclosporin A capsules orally, in 2 divided doses, adjusted thereafter to maintain serum concentrations of 150-300 ng/mL during the first month. Subsequently, doses were adjusted to maintain a predefined range of trough serum concentrations of 100-250 ng/mL for up to 36 months.

| | |
|-----------------------|--------------------------|
| Reporting group title | Belatacept MI (Period 2) |
|-----------------------|--------------------------|

Reporting group description:

Subjects in more intensive (MI) regimen during long term extension continued to receive belatacept at a maintenance dose of 5 mg/kg intravenously every 4 weeks for up to 84 months.

| | |
|-----------------------|--------------------------|
| Reporting group title | Belatacept LI (Period 2) |
|-----------------------|--------------------------|

Reporting group description:

Subjects in less intensive (LI) regimen during long term extension continued to receive belatacept at a maintenance dose of 5 mg/kg intravenously every 4 weeks for up to 84 months.

| | |
|-----------------------|--------------------------|
| Reporting group title | Cyclosporin A (Period 2) |
|-----------------------|--------------------------|

Reporting group description:

Subjects during the long-term extension continued to receive doses that were adjusted to maintain a predefined range of trough serum concentrations of 100-250 ng/mL for up to 84 months.

| | |
|----------------------------|-----------------------------|
| Subject analysis set title | Belatacept MI (Periods 1&2) |
|----------------------------|-----------------------------|

| | |
|---------------------------|--------------------|
| Subject analysis set type | Intention-to-treat |
|---------------------------|--------------------|

Subject analysis set description:

Intention-to-treat (ITT) Population

| | |
|----------------------------|-----------------------------|
| Subject analysis set title | Belatacept LI (Periods 1&2) |
|----------------------------|-----------------------------|

| | |
|---------------------------|--------------------|
| Subject analysis set type | Intention-to-treat |
|---------------------------|--------------------|

Subject analysis set description:

intention-to-treat (ITT) population

| | |
|----------------------------|-----------------------------|
| Subject analysis set title | Cyclosporin A (Periods 1&2) |
|----------------------------|-----------------------------|

| | |
|---------------------------|--------------------|
| Subject analysis set type | Intention-to-treat |
|---------------------------|--------------------|

Subject analysis set description:

Intention-to-Treat (ITT) population

Primary: Percentage of Subjects Who Survived With a Graft at 12 Months Post-Transplant

| | |
|-----------------|---|
| End point title | Percentage of Subjects Who Survived With a Graft at 12 Months Post-Transplant |
|-----------------|---|

End point description:

Subject and graft survival at 12 months was summarized within each treatment group. Graft loss was defined as either functional loss or physical loss (nephrectomy). Functional loss will be defined as a sustained level of serum creatinine ≥ 6.0 mg/dL (530 μ mol/L) as determined by central laboratory for \geq

4 weeks or 56 or more consecutive days of dialysis. The analysis was performed in the Intent-to-Treat population which includes all the subjects who are randomized into the study and received a transplant. Patients whose death or graft loss status was missing at Month 12 were imputed to have experienced death or graft loss if one or more of the criteria pre-specified in the statistical analysis plan for the study were met.

| | |
|--------------------------|---------|
| End point type | Primary |
| End point timeframe: | |
| Month 12 post-transplant | |

| End point values | Belatacept MI (Period 1) | Belatacept LI (Period 1) | Cyclosporin A (Period 1) | |
|----------------------------------|--------------------------|--------------------------|--------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 184 | 175 | 184 | |
| Units: Percentage of Subjects | | | | |
| number (confidence interval 95%) | 85.9 (80.8 to 90.9) | 88 (83.2 to 92.8) | 84.8 (79.6 to 90) | |

Statistical analyses

| | |
|--|---|
| Statistical analysis title | Subject and Graft Survival of Belatacept MI |
| Statistical analysis description: | |
| The treatment differences between each belatacept MI treatment group and cyclosporine group was tested at the 0.027 significance level for subject and graft survival (based on 10% non-inferiority margin). | |
| Comparison groups | Belatacept MI (Period 1) v Cyclosporin A (Period 1) |
| Number of subjects included in analysis | 368 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Treatment Difference |
| Point estimate | 1.1 |
| Confidence interval | |
| level | Other: 97.3 % |
| sides | 2-sided |
| lower limit | -7.2 |
| upper limit | 9.4 |

| | |
|--|---|
| Statistical analysis title | Subject and Graft Survival of Belatacept LI |
| Statistical analysis description: | |
| The treatment differences between each belatacept LI treatment group and cyclosporine group was tested at the 0.027 significance level for subject and graft survival (based on 10% non-inferiority margin). | |
| Comparison groups | Cyclosporin A (Period 1) v Belatacept LI (Period 1) |

| | |
|---|----------------------|
| Number of subjects included in analysis | 359 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Treatment Difference |
| Point estimate | 3.2 |
| Confidence interval | |
| level | Other: 97.3 % |
| sides | 2-sided |
| lower limit | -5 |
| upper limit | 11.4 |

Primary: Percentage of Subjects with a Measured Glomerular Filtration Rate (GFR) <60 mL/min per 1.73 m² at Month 12 or a Decrease in Measured GFR ≥10 mL/min per 1.73 m² from Month 3 to Month 12

| | |
|------------------------|--|
| End point title | Percentage of Subjects with a Measured Glomerular Filtration Rate (GFR) <60 mL/min per 1.73 m ² at Month 12 or a Decrease in Measured GFR ≥10 mL/min per 1.73 m ² from Month 3 to Month 12 |
| End point description: | GFR was assessed using a true measure of glomerular filtration via non-radiolabeled iothalamate clearance test using a validated procedure. The analysis was performed in the Intent-to-Treat population. Missing measured GFR assessments were imputed as having a GFR of zero. |
| End point type | Primary |
| End point timeframe: | From Month 3 to Month 12 |

| End point values | Belatacept MI (Period 1) | Belatacept LI (Period 1) | Cyclosporin A (Period 1) | |
|---|--------------------------|--------------------------|--------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 184 | 175 | 184 | |
| Units: Percentage of subjects | | | | |
| number (not applicable) | | | | |
| Measured GFR <60 mL/min/1.73 m ² at month 12 | 55.7 | 62.1 | 67.4 | |
| GFR of ≥ 10 mL/min/1.73 m ² from months 3-12 | 17.6 | 27.2 | 24.7 | |

Statistical analyses

| | |
|-----------------------------------|---|
| Statistical analysis title | Measured GFR of Belatacept MI |
| Statistical analysis description: | A continuity-corrected chi-square test (at the significance level 0.027) was performed to assess the effect of each belatacept regimen on renal function compared with CsA. 2-sided 97.3% CIs were generated for the difference in the percentage of subjects meeting the composite renal function endpoint between belatacept MI regimen and cyclosporine. |
| Comparison groups | Belatacept MI (Period 1) v Cyclosporin A (Period 1) |

| | |
|---|-----------------------|
| Number of subjects included in analysis | 368 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0018 |
| Method | Chi-squared |
| Parameter estimate | Percentage Difference |
| Point estimate | -14.4 |
| Confidence interval | |
| level | Other: 97.3 % |
| sides | 2-sided |
| lower limit | -24 |
| upper limit | -4.7 |

| | |
|-----------------------------------|-------------------------------|
| Statistical analysis title | Measured GFR of Belatacept LI |
|-----------------------------------|-------------------------------|

Statistical analysis description:

A continuity-corrected chi-square test (at the significance level 0.027) was performed to assess the effect of each belatacept regimen on renal function compared with CsA. 2-sided 97.3% CIs were generated for the difference in the Percentage of subjects meeting the composite renal function endpoint between belatacept LI regimen and cyclosporine.

| | |
|---|---|
| Comparison groups | Cyclosporin A (Period 1) v Belatacept LI (Period 1) |
| Number of subjects included in analysis | 359 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0616 |
| Method | Chi-squared |
| Parameter estimate | Percentage Difference |
| Point estimate | -8.5 |
| Confidence interval | |
| level | Other: 97.3 % |
| sides | 2-sided |
| lower limit | -18 |
| upper limit | 0.9 |

Secondary: Measured Glomerular Filtration Rate (GFR) by Month 12 and 24

| | |
|-----------------|--|
| End point title | Measured Glomerular Filtration Rate (GFR) by Month 12 and 24 |
|-----------------|--|

End point description:

GFR was assessed using a true measure of glomerular filtration via a non-radiolabeled iothalamate clearance test using a validated procedure. The analysis was performed in the Intent-to-Treat population. Missing measured GFR assessments were imputed to a GFR of zero. Here, 'n' signifies the number of evaluable subjects for the reporting arm at the given time point.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Month 12, and 24

| End point values | Belatacept MI (Period 1) | Belatacept LI (Period 1) | Cyclosporin A (Period 1) | |
|--------------------------------------|-----------------------------|-----------------------------|-----------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 184 | 175 | 184 | |
| Units: mL/min/1.73 m ² | | | | |
| arithmetic mean (standard deviation) | | | | |
| Month 12 | 52.1 (± 21.9) | 49.5 (± 25.4) | 45.2 (± 21.1) | |
| Month 24 | 51.5 (± 22.9) | 49.7 (± 23.67) | 45 (± 27.18) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects with Chronic Allograft Nephropathy (CAN) at Month 12

| | |
|-----------------|---|
| End point title | Percentage of Subjects with Chronic Allograft Nephropathy (CAN) at Month 12 |
|-----------------|---|

End point description:

Biopsy-proven CAN was determined by a blinded central histopathologist using the Banff 97 working classification of kidney transplant pathology. Onset of CAN was determined by the biopsy date when it was observed. Subjects were considered as having CAN at 12 months if: CAN observed in a biopsy either prior to 12 months (including baseline biopsy) or first post 12 months biopsy; Subject had graft loss during the first year post transplant; no biopsy available post 12 months and CAN not observed in biopsies prior to 12 months; no biopsy available either prior to or post 12 months; and the measured glomerular filtration rate from Month 3 to Month 12 decreases at least 10 mL/min/1.73m². All other subjects with missing 12 month biopsy were considered having no CAN observed at 12 months. The analysis was performed in the Intent-to-Treat population.

| | |
|----------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Month 12 | |

| End point values | Belatacept MI (Period 1) | Belatacept LI (Period 1) | Cyclosporin A (Period 1) | |
|----------------------------------|-----------------------------|-----------------------------|-----------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 184 | 175 | 184 | |
| Units: Percentage of Subjects | | | | |
| number (confidence interval 95%) | 44.8 (37.6 to 52) | 46 (38.6 to 53.4) | 51.6 (44.4 to 58.9) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Who Survived With a Graft at 24 and 36 Months Post-Transplant

| | |
|-----------------|--|
| End point title | Percentage of Subjects Who Survived With a Graft at 24 and 36 Months Post-Transplant |
|-----------------|--|

End point description:

Subject and graft survival at 24 and 36 months was summarized within each treatment group. Graft loss was defined as either functional loss or physical loss (nephrectomy). Functional loss was defined as a sustained level of serum creatinine ≥ 6.0 mg/dL (530 $\mu\text{mol/L}$) as determined by central laboratory for ≥ 4 weeks or 56 or more consecutive days of dialysis. The analysis was performed in the Intent-to-Treat population which includes all the subjects who were randomized into the study and received a transplant.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Month 24 and 36 post-transplant

| End point values | Belatacept MI (Period 1) | Belatacept LI (Period 1) | Cyclosporin A (Period 1) | |
|----------------------------------|-----------------------------|-----------------------------|-----------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 184 | 175 | 184 | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | | | | |
| Month 24 | 82.6 (77.1 to 88.1) | 84 (78.6 to 89.4) | 82.6 (77.1 to 88.1) | |
| Month 36 | 80.4 (74.7 to 86.2) | 82.3 (76.6 to 87.9) | 79.9 (74.1 to 85.7) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Calculated Glomerular Filtration Rate (GFR) at 6, 12, 24, 36 and 84 Months

| | |
|-----------------|--|
| End point title | Calculated Glomerular Filtration Rate (GFR) at 6, 12, 24, 36 and 84 Months |
|-----------------|--|

End point description:

GFR was assessed using a true measure of glomerular filtration via non-radiolabeled iothalamate clearance test using a validated procedure. The analysis was performed in the Intent-to-Treat population. Missing measured GFR assessments were imputed as a GFR of zero. Here 'n' signifies those subjects evaluable for this measure at specified time points for each arm, respectively.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Month 6, 12, 24, 36 and 84

| End point values | Belatacept MI (Periods 1&2) | Belatacept LI (Periods 1&2) | Cyclosporin A (Periods 1&2) | |
|--------------------------------------|--------------------------------|--------------------------------|--------------------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 184 | 175 | 184 | |
| Units: mL/min/1.73 m ² | | | | |
| arithmetic mean (standard deviation) | | | | |
| Month 6 (n = 161,152,153) | 43.6 (\pm 21.67) | 43.4 (\pm 18.57) | 35.5 (\pm 20.51) | |
| Month 12 (n = 159,154,154) | 44.4 (\pm 22.78) | 44.8 (\pm 21.57) | 36.5 (\pm 21.08) | |

| | | | | |
|----------------------------|----------------|----------------|----------------|--|
| Month 24 (n = 152,158,154) | 44.4 (± 26.72) | 42.8 (± 24.07) | 34.9 (± 21.59) | |
| Month 36 (n = 152,154,143) | 42.7 (± 27.59) | 42.2 (± 25.2) | 31.5 (± 22.13) | |
| Month 84 (n = 69,79,51) | 57.6 (± 18.58) | 59.1 (± 18.85) | 44.6 (± 17.37) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change in Calculated GFR from Month 3 to 12, 24, 36 and 84

| | |
|-----------------|--|
| End point title | Change in Calculated GFR from Month 3 to 12, 24, 36 and 84 |
|-----------------|--|

End point description:

GFR was assessed using a true measure of glomerular filtration via non-radiolabeled iothalamate clearance test using a validated procedure. The analysis was performed in the Intent-to-Treat population. Missing measured GFR assessments were imputed to a GFR of zero. Here 'n' signifies those subjects evaluable for this measure at specified time points for each arm, respectively.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Month 12, 24, 36 and 84

| End point values | Belatacept MI (Periods 1&2) | Belatacept LI (Periods 1&2) | Cyclosporin A (Periods 1&2) | |
|--------------------------------------|--------------------------------|--------------------------------|--------------------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 184 | 175 | 184 | |
| Units: mL/min/1.73 m ² | | | | |
| arithmetic mean (standard deviation) | | | | |
| Month 12 (n = 159,154,154) | -0.7 (± 17.96) | -0.6 (± 15.39) | -1.1 (± 12.48) | |
| Month 24 (n = 146,154,149) | -1.4 (± 17.68) | -1.6 (± 18.7) | -3.6 (± 15.37) | |
| Month 36 (n = 146,150,139) | -2.9 (± 23.7) | -2.1 (± 20.92) | -6.1 (± 17.39) | |
| Month 84 (n = 67,76,49) | 7.5 (± 17.48) | 10.4 (± 17.54) | -4 (± 17.17) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with Anti-Hypertensive Medications Used to Control Hypertension at 12, 24 and 36 Months

| | |
|-----------------|--|
| End point title | Number of Subjects with Anti-Hypertensive Medications Used to Control Hypertension at 12, 24 and 36 Months |
|-----------------|--|

End point description:

Subjects were determined to have hypertension at a particular time point if standardized SBP ≥ 130 mm Hg or standardized DBP ≥ 80 mm Hg or subject had received an antihypertensive medication(s) for hypertension. The analysis was performed in the Intent-to-Treat population. Here 'n' signifies those subjects evaluable for this measure at specified time points for each arm, respectively.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Month 12, 24, 36

| End point values | Belatacept MI (Period 1) | Belatacept LI (Period 1) | Cyclosporin A (Period 1) | |
|--|-----------------------------|-----------------------------|-----------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 184 | 175 | 184 | |
| Units: Number of subjects | | | | |
| 1-2 Medications (Month 12) (n=184,175,184) | 82 | 79 | 76 | |
| ≥ 3 Medications (Month 12) (n=184,175,184) | 76 | 66 | 93 | |
| 1-2 Medications (Month 24) (n=177,170,179) | 80 | 79 | 71 | |
| ≥ 3 Medications (Month 24) (n=177,170,179) | 78 | 65 | 89 | |
| 1-2 Medications (Month 36) (n=151,145,143) | 65 | 67 | 51 | |
| ≥ 3 Medications (Month 36) (n=151,145,143) | 70 | 60 | 79 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Who Used Anti-Hypertensive Medications to Control Hypertension at Month 12, 24 and 36

| | |
|-----------------|--|
| End point title | Percentage of Subjects Who Used Anti-Hypertensive Medications to Control Hypertension at Month 12, 24 and 36 |
|-----------------|--|

End point description:

Subjects were determined to have hypertension at a particular time point if standardized SBP ≥ 130 mm Hg or standardized DBP ≥ 80 mm Hg or subject had received an antihypertensive medication(s) for hypertension. The analysis was performed in the Intent-to-Treat population. Here 'n' signifies those subjects evaluable for this measure at specified time points for each arm, respectively.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Month 12, 24, 36

| End point values | Belatacept MI (Period 1) | Belatacept LI (Period 1) | Cyclosporin A (Period 1) | |
|----------------------------------|-----------------------------|-----------------------------|-----------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 184 | 175 | 184 | |
| Units: Percentage of subject | | | | |
| number (confidence interval 95%) | | | | |
| Month 12 (n = 184,175,184) | 87 (82.09 to 91.82) | 83.4 (77.92 to 88.94) | 87 (82.09 to 91.82) | |
| Month 24 (n = 177,170,179) | 89.3 (84.71 to 93.83) | 84.7 (79.3 to 90.12) | 89.4 (84.87 to 93.9) | |
| Month 36 (n = 151,145,143) | 89.4 (84.49 to 94.31) | 87.6 (82.22 to 92.25) | 90.9 (86.2 to 95.62) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects with New Onset Diabetes Mellitus (NODM) at 12, 24 and 36 Months

| | |
|-----------------|--|
| End point title | Percentage of Subjects with New Onset Diabetes Mellitus (NODM) at 12, 24 and 36 Months |
|-----------------|--|

End point description:

NODM was defined as subject who did not have diabetes prior to randomization. Subjects were determined for NODM if the subject received an antidiabetic medication for a duration of at least 30 days, or at least two fasting plasma glucose (FPG) tests indicate that FPG is ≥ 126 mg/dL (7.0 mmol/L). The analysis was performed in the Intent-to-Treat population.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Month 12, 24, 36

| End point values | Belatacept MI (Period 1) | Belatacept LI (Period 1) | Cyclosporin A (Period 1) | |
|-------------------------------|--------------------------|--------------------------|--------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 184 | 175 | 184 | |
| Units: Percentage of subjects | | | | |
| number (not applicable) | | | | |
| 12 Month | 2.3 | 5.1 | 9.3 | |
| 24 Month | 3 | 7.4 | 9.3 | |
| 36 Month | 5.3 | 9.6 | 9.3 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Systolic and Diastolic Blood Pressure at 12, 24 and 36 Months

| | |
|-----------------|---|
| End point title | Systolic and Diastolic Blood Pressure at 12, 24 and 36 Months |
|-----------------|---|

End point description:

Subjects were determined to have hypertension at a particular time point if standardized SBP ≥ 130 mm Hg or standardized DBP ≥ 80 mm Hg or subject had received an antihypertensive medication(s) for hypertension. The analysis was performed in the Intent-to-Treat population. Here 'n' signifies those subjects evaluable for this measure at specified time points for each arm, respectively.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Month 12, 24, 36

| End point values | Belatacept MI (Period 1) | Belatacept LI (Period 1) | Cyclosporin A (Period 1) | |
|---|-----------------------------|-----------------------------|-----------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 184 | 175 | 184 | |
| Units: mmHg | | | | |
| arithmetic mean (standard deviation) | | | | |
| Diastolic BP (Month 12) (n=184,175,184) | 77.8 (± 13.83) | 78.3 (± 10.62) | 81.8 (± 11.68) | |
| Systolic BP (Month 12) (n=184,175,184) | 141.4 (± 21.29) | 140.9 (± 21.09) | 149.5 (± 19.81) | |
| Diastolic BP (Month 24) (n=120,129,120) | 78.2 (± 13.28) | 77 (± 11.18) | 81.7 (± 11.47) | |
| Systolic BP (Month 24) (n=120,129,120) | 138.8 (± 24.31) | 136.7 (± 20.96) | 146.8 (± 21.11) | |
| Diastolic BP (Month 36) (n=112,119,108) | 75.4 (± 11.55) | 75.2 (± 10.85) | 77.2 (± 11.79) | |
| Systolic BP (Month 36) (n=112,119,108) | 134.9 (± 19.54) | 134.7 (± 21.59) | 140.7 (± 21.19) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Framingham Risk Score from Baseline to Month 12, 24 and 36

| | |
|------------------------|--|
| End point title | Mean Framingham Risk Score from Baseline to Month 12, 24 and 36 |
| End point description: | The risk score utilized data from the Framingham Heart Study to estimate 10-year risk for 'hard' coronary heart disease (myocardial infarction and coronary death). The risk factors included were age, gender, total cholesterol, HDL cholesterol, SBP, diabetes, treatment for hypertension, and any cigarette use in the prior month. The analysis was performed in the Intent-to-Treat population. |
| End point type | Secondary |
| End point timeframe: | Month 12, 24, 36 |

| End point values | Belatacept MI (Period 1) | Belatacept LI (Period 1) | Cyclosporin A (Period 1) | |
|--------------------------------------|-----------------------------|-----------------------------|-----------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 184 | 175 | 184 | |
| Units: Score on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Month 12 | 5.3 (± 4.11) | 4.5 (± 4.02) | 6 (± 3.98) | |
| Month 24 | 5 (± 4.25) | 4.6 (± 4.23) | 6.2 (± 4.07) | |
| Month 36 | 5.2 (± 4.18) | 4.9 (± 3.84) | 5.8 (± 4) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Using Lipid-Lowering Therapy at 12, 24, and 36 Months

| | |
|-----------------|--|
| End point title | Percentage of Subjects Using Lipid-Lowering Therapy at 12, 24, and 36 Months |
|-----------------|--|

End point description:

Dyslipidemia was defined as triglyceride \geq 500 mg/dL [5.65 mmol/L], low-density lipoprotein (LDL) \geq 100 mg/dL [2.59 mmol/L], and elevated non-high density lipoprotein (HDL) \geq 130 mg/dL [3.36 mmol/L]. The analysis was performed in the Intent-to-Treat population. Here 'n' signifies those subjects evaluable for this measure at specified time points for each arm, respectively.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Month 12, 24, 36

| End point values | Belatacept MI (Period 1) | Belatacept LI (Period 1) | Cyclosporin A (Period 1) | |
|----------------------------------|-----------------------------|-----------------------------|-----------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 184 | 175 | 184 | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | | | | |
| Month 12 (n = 184,175,184) | 43.5 (36.3 to 50.6) | 40 (32.7 to 47.3) | 46.2 (39 to 53.2) | |
| Month 24 (n = 184,175,184) | 47.8 (40.6 to 55) | 42.3 (35 to 49.6) | 51.1 (43.9 to 58.3) | |
| Month 36 (n = 151,145,143) | 52.3 (44.4 to 60.3) | 45.5 (37.4 to 53.6) | 60.8 (52.8 to 68.8) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change in Total Cholesterol, Non-HDL, LDL and HDL Cholesterol and Triglyceride at 12, 24 and 36 Months

| | |
|-----------------|--|
| End point title | Change in Total Cholesterol, Non-HDL, LDL and HDL Cholesterol and Triglyceride at 12, 24 and 36 Months |
|-----------------|--|

End point description:

Dyslipidemia was defined as triglyceride \geq 500 mg/dL [5.65 mmol/L], low-density lipoprotein (LDL) \geq 100 mg/dL [2.59 mmol/L], and elevated non-high density lipoprotein (HDL) \geq 130 mg/dL [3.36 mmol/L]. The analysis was performed in the Intent-to-Treat population. Here 'n' signifies those subjects evaluable for this measure at specified time points for each arm, respectively.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Month 12, 24, 36

| End point values | Belatacept MI (Period 1) | Belatacept LI (Period 1) | Cyclosporin A (Period 1) | |
|--|-----------------------------|-----------------------------|-----------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 184 | 175 | 184 | |
| Units: mg/dL | | | | |
| arithmetic mean (standard deviation) | | | | |
| Non-HDL (Month 12) (n = 184,175,184) | 134.5 (± 45.04) | 134.2 (± 40.69) | 153.4 (± 46.69) | |
| Total Cholesterol (Month 12) (n = 184,175,184) | 183.7 (± 47.72) | 184.1 (± 45.51) | 201.3 (± 49.49) | |
| Triglyceride (Month 12) (n = 184,175,184) | 171.9 (± 129.76) | 153.2 (± 69.92) | 213.8 (± 113.12) | |
| HDL (Month 12) (n = 184,175,184) | 49.2 (± 13.73) | 49.8 (± 15.85) | 47.9 (± 14.76) | |
| LDL (Month 12) (n = 184,175,184) | 104 (± 39.33) | 102.4 (± 36.63) | 107.8 (± 40.08) | |
| Non-HDL (Month 24) (n = 119,128,111) | 126.1 (± 45.45) | 129.8 (± 37.89) | 148.7 (± 60.46) | |
| Total Cholesterol (Month 24) (n = 119,128,111) | 175.6 (± 47.99) | 178 (± 41.9) | 195.7 (± 61.46) | |
| Triglyceride (Month 24) (n = 98,104,93) | 152 (± 108.97) | 147 (± 69.45) | 208.2 (± 135.19) | |
| HDL (Month 24) (n = 119,128,111) | 49.5 (± 16.27) | 48.2 (± 14.41) | 47 (± 17.77) | |
| LDL (Month 24) (n = 97,104,93) | 96.9 (± 33.46) | 101.4 (± 36.64) | 108.6 (± 40.8) | |
| Non-HDL (Month 36) (n = 111,117,97) | 132.6 (± 41.86) | 132.2 (± 46.81) | 139.1 (± 49.68) | |
| Total Cholesterol (Month 36) (n = 111,117,98) | 181 (± 43.84) | 181.9 (± 49.16) | 196.7 (± 127.35) | |
| Triglyceride (Month 36) (n = 80,88,78) | 160.7 (± 98.56) | 154.3 (± 76.58) | 181.3 (± 108.32) | |
| HDL (Month 36) (n = 111,117,97) | 48.9 (± 14.82) | 49.6 (± 16.24) | 47 (± 14.28) | |
| LDL (Month 36) (n = 79,88,77) | 103.1 (± 32.59) | 106 (± 37.29) | 102.3 (± 47.4) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Who Have an Acute Rejection by Month 6, 12, 24, 36 and 84

| | |
|-----------------|--|
| End point title | Percentage of Subjects Who Have an Acute Rejection by Month 6, 12, 24, 36 and 84 |
|-----------------|--|

End point description:

Acute rejection was defined as central biopsy proven rejection that was either clinically suspected by protocol defined reasons or clinically suspected by other reasons and treated. Clinically suspected acute rejection was defined as an unexplained rise of serum creatinine $\geq 25\%$ from baseline creatinine or an unexplained decreased urine output or fever and graft tenderness or serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. The analysis was performed in the Intent-to-Treat population.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Month 6, 12, 24, 36 and 84

| End point values | Belatacept MI (Periods 1&2) | Belatacept LI (Periods 1&2) | Cyclosporin A (Periods 1&2) | |
|----------------------------------|--------------------------------|--------------------------------|--------------------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 184 | 175 | 184 | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | | | | |
| Month 6 | 17.4 (11.9 to 22.9) | 16.6 (11.1 to 22.1) | 13.6 (8.6 to 18.5) | |
| Month 12 | 17.4 (11.9 to 22.9) | 17.7 (12.1 to 23.4) | 14.1 (9.1 to 19.2) | |
| Month 24 | 17.4 (11.9 to 22.9) | 18.3 (12.6 to 24) | 15.2 (10 to 20.4) | |
| Month 36 | 17.9 (12.4 to 23.5) | 18.9 (13.1 to 24.7) | 15.8 (10.5 to 21.1) | |
| Month 84 | 19 (13.4 to 24.7) | 19.4 (13.6 to 25.3) | 15.8 (10.5 to 21.1) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects Using Lymphocyte Depleting Therapy and Steroid-Resistant for Acute Rejection by Month 6, 12, 24, and 36

| | |
|-----------------|--|
| End point title | Number of Subjects Using Lymphocyte Depleting Therapy and Steroid-Resistant for Acute Rejection by Month 6, 12, 24, and 36 |
|-----------------|--|

End point description:

Acute rejection was defined as central biopsy proven rejection that was either clinically suspected by protocol defined reasons or clinically suspected by other reasons and treated. Lymphocyte-depletion therapy for treatment of an episode of acute was defined as subject treated with therapy and provided not treated with steroids earlier while steroid resistant acute rejection was defined as subjects initially treated with steroids alone for suspected acute rejection for at least 2 days and then followed by the start of lymphocyte-depletion therapy. The analysis was performed in the Intent-to-Treat population.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Month 6, 12, 24, 36

| End point values | Belatacept MI (Period 1) | Belatacept LI (Period 1) | Cyclosporin A (Period 1) | |
|---------------------------------------|-----------------------------|-----------------------------|-----------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 184 | 175 | 184 | |
| Units: Number of subjects | | | | |
| number (not applicable) | | | | |
| Only corticosteroid treated (Month 6) | 14 | 16 | 9 | |
| Corticosteroid resistant (Month 6) | 2 | 2 | 2 | |

| | | | | |
|---|----|----|----|--|
| Lymphocyte-depleting treated (Month 6) | 13 | 5 | 4 | |
| Only corticosteroid treated (Month 12) | 14 | 16 | 10 | |
| Corticosteroid resistant (Month 12) | 2 | 2 | 2 | |
| Lymphocyte-depleting treated (Month 12) | 13 | 5 | 4 | |
| Only corticosteroid treated (Month 24) | 13 | 19 | 11 | |
| Corticosteroid resistant (Month 24) | 2 | 1 | 2 | |
| Lymphocyte-depleting treated (Month 24) | 14 | 7 | 4 | |
| Only corticosteroid treated (Month 36) | 13 | 19 | 11 | |
| Corticosteroid resistant (Month 36) | 2 | 1 | 2 | |
| Lymphocyte-depleting treated (Month 36) | 14 | 7 | 4 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects Based on Severity of Acute Rejection Based on Banff Grade Level by Months 6, 12, 24, 36 and 84.

| | |
|-----------------|--|
| End point title | Number of Subjects Based on Severity of Acute Rejection Based on Banff Grade Level by Months 6, 12, 24, 36 and 84. |
|-----------------|--|

End point description:

Acute rejection was defined as central biopsy proven rejection that was either clinically suspected by protocol defined reasons or clinically suspected by other reasons and treated. Clinically suspected acute rejection was defined as an unexplained rise of serum creatinine $\geq 25\%$ from baseline creatinine or an unexplained decreased urine output or fever and graft tenderness or serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. The analysis was performed in the Intent-to-Treat population.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Month 6, 12, 24, 36 and 84

| End point values | Belatacept MI (Periods 1&2) | Belatacept LI (Periods 1&2) | Cyclosporin A (Periods 1&2) | |
|---------------------------------|-----------------------------|-----------------------------|-----------------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 184 | 175 | 184 | |
| Units: Subjects | | | | |
| Mild acute (IA) (Month 6) | 0 | 4 | 2 | |
| Mild acute (IB) (Month 6) | 6 | 2 | 2 | |
| Moderate acute (IIA) (Month 6) | 11 | 15 | 16 | |
| Moderate acute (IB) (Month 6) | 15 | 8 | 5 | |
| Severe acute (III) (Month 6) | 0 | 0 | 0 | |
| Mild acute (IA) (Month 12) | 0 | 4 | 2 | |
| Mild acute (IB) (Month 12) | 6 | 2 | 2 | |
| Moderate acute (IIA) (Month 12) | 11 | 17 | 17 | |
| Moderate acute (IB) (Month 12) | 15 | 8 | 5 | |
| Severe acute (III) (Month 12) | 0 | 0 | 0 | |
| Mild acute (IA) (Month 24) | 0 | 4 | 2 | |
| Mild acute (IB) (Month 24) | 6 | 2 | 3 | |

| | | | | |
|---------------------------------|----|----|----|--|
| Moderate acute (IIA) (Month 24) | 10 | 17 | 18 | |
| Moderate acute (IB) (Month 24) | 16 | 9 | 5 | |
| Severe acute (III) (Month 24) | 0 | 0 | 0 | |
| Mild acute (IA) (Month 36) | 0 | 4 | 2 | |
| Mild acute (IB) (Month 36) | 6 | 2 | 4 | |
| Moderate acute (IIA) (Month 36) | 10 | 18 | 18 | |
| Moderate acute (IB) (Month 36) | 16 | 9 | 5 | |
| Severe acute (III) (Month 36) | 1 | 0 | 0 | |
| Mild acute (IA) (Month 84) | 0 | 4 | 2 | |
| Mild acute (IB) (Month 84) | 6 | 3 | 4 | |
| Moderate acute (IIA) (Month 84) | 12 | 18 | 18 | |
| Moderate acute (IIB) (Month 84) | 16 | 9 | 5 | |
| Severe acute (III) (Month 84) | 1 | 0 | 0 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Changes in Mental Component and Physical Component Health-Related Quality of Life (SF-36) from Baseline to Months 12, 24 and 36

| | |
|-----------------|--|
| End point title | Mean Changes in Mental Component and Physical Component Health-Related Quality of Life (SF-36) from Baseline to Months 12, 24 and 36 |
|-----------------|--|

End point description:

The SF-36 was used to measure health-related quality of life (QoL). Individual subscale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) and 2 summary scores (physical component score and mental component score) were calculated. The analysis was performed in the Intent-to-Treat population. Here 'n' signifies those subjects evaluable for this measure at specified time points for each arm, respectively.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Month 12, 24, 36

| End point values | Belatacept MI (Period 1) | Belatacept LI (Period 1) | Cyclosporin A (Period 1) | |
|---|--------------------------|--------------------------|--------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 184 | 175 | 184 | |
| Units: Score on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Physical functioning (Month 12) (n=148, 153, 155) | 44.7 (± 10.56) | 46 (± 11.01) | 44 (± 10.64) | |
| Role-physical (Month 12) (n=148, 153, 156) | 43.6 (± 11.24) | 43.9 (± 11.45) | 42.3 (± 10.86) | |
| Bodily pain (Month 12) (n=148, 153, 154) | 52.5 (± 10.81) | 49.9 (± 12) | 48.3 (± 11.23) | |
| General health (Month 12) (n=148, 154, 156) | 47.6 (± 9.55) | 46.9 (± 9.87) | 46 (± 9.92) | |
| Vitality (Month 12) (n=147, 152, 156) | 53.5 (± 9.9) | 53.3 (± 11.54) | 51.9 (± 10.63) | |
| Social functioning (Month 12) (n=148, 153, 156) | 48.7 (± 9.8) | 47 (± 11.22) | 45.4 (± 11.53) | |

| | | | |
|---|----------------|----------------|----------------|
| Role-emotional (Month 12) (n=148, 152, 154) | 44.1 (± 12.38) | 43.5 (± 13.68) | 44.1 (± 12.27) |
| Mental health (Month 12) (n=147, 151, 156) | 50.1 (± 10.56) | 49.1 (± 12.43) | 49.1 (± 11.29) |
| Physical functioning (Month 24) (n=145, 151, 153) | 43.9 (± 10.77) | 46 (± 10.2) | 43.1 (± 11.47) |
| Role-physical (Month 24) (n=145, 150, 151) | 43.4 (± 11.17) | 43.9 (± 10.58) | 42.1 (± 10.76) |
| Bodily pain (Month 24) (n=144, 152, 152) | 51.4 (± 11.09) | 49.2 (± 11.45) | 47.2 (± 11.87) |
| General health (Month 24) (n=147, 152, 154) | 46.8 (± 9.37) | 46.5 (± 10.1) | 44.6 (± 10.49) |
| Vitality (Month 24) (n=145, 150, 153) | 53.3 (± 9.8) | 52.9 (± 11.31) | 50.5 (± 11.07) |
| Social functioning (Month 24) (n=146, 152, 153) | 47.2 (± 10.87) | 48.7 (± 9.35) | 45.7 (± 11.5) |
| Role-emotional (Month 24) (n=144, 148, 147) | 44.5 (± 12.38) | 44.3 (± 12.43) | 43.6 (± 12.37) |
| Mental health (Month 24) (n=145, 150, 153) | 50.1 (± 10.59) | 49.3 (± 11.81) | 48.2 (± 11.5) |
| Physical functioning (Month 36) (n=144, 151, 153) | 43.8 (± 11.66) | 45.5 (± 10.84) | 43 (± 11.77) |
| Role-physical (Month 36) (n=144, 148, 152) | 43.9 (± 11) | 43.5 (± 11.08) | 41.9 (± 11.15) |
| Bodily pain (Month 36) (n=143, 151, 153) | 51.1 (± 11.19) | 49.5 (± 11.76) | 46.9 (± 11.16) |
| General health (Month 36) (n=147, 152, 154) | 46.3 (± 9.96) | 45.4 (± 10.5) | 43.6 (± 10.51) |
| Vitality (Month 36) (n=144, 149, 153) | 53.5 (± 10.07) | 52.3 (± 11.94) | 50.5 (± 11.26) |
| Social functioning (Month 36) (n=146, 152, 154) | 46.9 (± 10.64) | 48.3 (± 10.1) | 45.1 (± 11.57) |
| Role-emotional (Month 36) (n=144, 146, 148) | 44.2 (± 12.74) | 43.5 (± 12.73) | 43.1 (± 12.96) |
| Mental health (Month 36) (n=144, 149, 153) | 50.8 (± 9.35) | 48.1 (± 12.31) | 47.7 (± 11.19) |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with Clinically Significant Changes in Vital Signs up to 36 Months

| | |
|---|---|
| End point title | Number of Subjects with Clinically Significant Changes in Vital Signs up to 36 Months |
| End point description: Subjects with abnormal blood pressure, body weight and body temperature outside the defined normal range were graded as clinically significant vital signs by the investigator. The analysis was performed in the Intent-to-Treat population. | |
| End point type | Secondary |
| End point timeframe: Baseline up to Month 36 | |

| End point values | Belatacept MI (Period 1) | Belatacept LI (Period 1) | Cyclosporin A (Period 1) | |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 184 | 175 | 184 | |
| Units: Subjects | | | | |
| Heart rate | 0 | 0 | 0 | |
| Body temperature | 0 | 0 | 0 | |
| Body weight | 0 | 0 | 0 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with Laboratory Test Abnormalities up to 36 Months

| | |
|-----------------|---|
| End point title | Number of Subjects with Laboratory Test Abnormalities up to 36 Months |
|-----------------|---|

End point description:

Subjects with laboratory values outside the defined normal range were graded as clinically significant laboratory abnormalities by the investigator. Subjects were analysed for Alkaline phosphatase (ALP), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Hemoglobin, Platelet Count, Leukocytes, Bilirubin, Creatinine, Calcium, Bicarbonate, Potassium, Magnesium, Sodium, Phosphorus, Albumin, Uric Acid and Protein. Laboratory abnormalities were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3. The analysis was performed in the Intent-to-Treat population. Here 'n' signifies those subjects evaluable for this measure at specified time points for each arm, respectively.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Month 36

| End point values | Belatacept MI (Period 1) | Belatacept LI (Period 1) | Cyclosporin A (Period 1) | |
|--|-----------------------------|-----------------------------|-----------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 184 | 175 | 184 | |
| Units: Subjects | | | | |
| Hemoglobin (Low) (n=177,172,181) | 25 | 24 | 16 | |
| Platelet Count (Low) (n=177,172,181) | 2 | 1 | 2 | |
| Leukocytes (Low) (n=177,172,181) | 10 | 5 | 8 | |
| ALP (High) (n=177,172,182) | 1 | 1 | 0 | |
| ALT (High) (n=177,172,181) | 4 | 2 | 4 | |
| AST (High) (n=177,172,181) | 1 | 1 | 0 | |
| Bilirubin, Total (High) (n=177,172,182) | 0 | 2 | 1 | |
| Creatinine (High) (n=177,172,182) | 125 | 117 | 128 | |
| Calcium, Total (Low) (n=177,172,182) | 19 | 14 | 10 | |
| Calcium, Total (High) (n=177,172,182) | 2 | 2 | 1 | |
| Bicarbonate (Low) (n=176,171,181) | 2 | 1 | 2 | |
| Bicarbonate (High) (n=176,171,181) | 0 | 0 | 0 | |
| Potassium, Serum (Low) (n=177,172,181) | 6 | 3 | 9 | |
| Potassium, Serum (High) (n=177,172,181) | 8 | 6 | 11 | |

| | | | | |
|--|----|----|----|--|
| Magnesium, Serum (Low) (n=177,172,181) | 6 | 3 | 1 | |
| Magnesium, Serum (High) (n=177,172,181) | 6 | 4 | 9 | |
| Sodium, Serum (Low) (n=177,172,182) | 18 | 16 | 23 | |
| Sodium, Serum (High) (n=177,172,182) | 0 | 0 | 1 | |
| Phosphorus (Low) (n=177,172,182) | 66 | 58 | 44 | |
| Albumin (Low) (n=177,172,182) | 2 | 4 | 1 | |
| Uric Acid (High) (n=177,172,182) | 31 | 34 | 60 | |
| Protein, Urine (High) (n=173,168,177) | 44 | 37 | 43 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with Adverse Events (AEs), Serious Adverse Events (SAEs), Related AEs and SAEs, AEs Leading to Discontinuation and Who Died up to Month 36

| | |
|-----------------|---|
| End point title | Number of Subjects with Adverse Events (AEs), Serious Adverse Events (SAEs), Related AEs and SAEs, AEs Leading to Discontinuation and Who Died up to Month 36 |
|-----------------|---|

End point description:

AEs are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards. The analysis was performed in the Intent-to-Treat population.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Month 36

| End point values | Belatacept MI (Period 1) | Belatacept LI (Period 1) | Cyclosporin A (Period 1) | |
|---------------------------------|-----------------------------|-----------------------------|-----------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 184 | 175 | 184 | |
| Units: Subjects | | | | |
| AEs | 182 | 174 | 184 | |
| SAEs | 149 | 139 | 146 | |
| AEs leading to Discontinuation | 34 | 36 | 44 | |
| SAEs leading to Discontinuation | 31 | 31 | 28 | |
| Related AEs | 115 | 106 | 141 | |
| Related SAEs | 60 | 51 | 58 | |
| Deaths | 22 | 15 | 17 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with Adverse Events (AEs), Serious Adverse Events (SAEs), Related AEs and SAEs, AEs Leading to Discontinuation and Who Died up to Month 84

| | |
|-----------------|---|
| End point title | Number of Subjects with Adverse Events (AEs), Serious Adverse Events (SAEs), Related AEs and SAEs, AEs Leading to Discontinuation and Who Died up to Month 84 |
|-----------------|---|

End point description:

AEs are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards. The analysis was performed in the Intent-to-Treat population.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Month 84

| End point values | Belatacept MI (Periods 1&2) | Belatacept LI (Periods 1&2) | Cyclosporin A (Periods 1&2) | |
|---------------------------------|--------------------------------|--------------------------------|--------------------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 184 | 175 | 184 | |
| Units: Subjects | | | | |
| AEs | 104 | 113 | 87 | |
| SAEs | 94 | 104 | 73 | |
| AEs leading to Discontinuation | 14 | 14 | 7 | |
| SAEs leading to Discontinuation | 10 | 13 | 7 | |
| Deaths | 14 | 21 | 9 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects with Graft Loss or Death to Month 84

| | |
|-----------------|---|
| End point title | Percentage of Subjects with Graft Loss or Death to Month 84 |
|-----------------|---|

End point description:

Subject and graft survival at 84 months was summarized within each treatment group. The analyses was performed in the Intent-to-Treat population which includes all subjects who are randomized into the study and received a transplant.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Randomization to date of death, up to 84 months

| End point values | Belatacept MI (Periods 1&2) | Belatacept LI (Periods 1&2) | Cyclosporin A (Periods 1&2) | |
|-------------------------------|--------------------------------|--------------------------------|--------------------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 184 | 175 | 184 | |
| Units: Percentage of Subjects | | | | |
| number (not applicable) | | | | |
| Graft Loss or Death | 29.3 | 30.9 | 28.3 | |
| Graft Loss | 11.4 | 13.1 | 15.8 | |
| Death | 20.1 | 21.1 | 15.8 | |
| Death with Functioning Graft | 17.9 | 17.7 | 12.5 | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From Baseline up to 56 days after the last dose of the study drug

Adverse event reporting additional description:

On treatment-period

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 13.0 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|---------------|
| Reporting group title | Belatacept MI |
|-----------------------|---------------|

Reporting group description:

Subjects in more intensive (MI) regimen received belatacept 10 mg/kg intravenous solution on Day 1 and 5 during the first week, and then every other week through 3 months (Weeks 2, 4, 8, and 12) and then every 4 weeks through 6 months (Weeks 16, 20 and 24), followed by a maintenance dose of belatacept, 5 mg/kg intravenously every 4 weeks thereafter for up to 84 months.

| | |
|-----------------------|---------------|
| Reporting group title | Belatacept LI |
|-----------------------|---------------|

Reporting group description:

Subjects in less intensive (LI) regimen received belatacept, 10 mg/kg intravenously on Day 1 and Day 5 during the first week, and then every other week for 4 weeks (Weeks 2 and 4), and then every 4 weeks for 2 months (Weeks 8 and 12), followed by a maintenance dose of belatacept, 5 mg/kg intravenously every 4 weeks thereafter for up to 84 months.

| | |
|-----------------------|---------------|
| Reporting group title | Cyclosporin A |
|-----------------------|---------------|

Reporting group description:

Subjects received an initial daily dose of 4 -10 mg/kg cyclosporine capsules orally, in 2 divided doses, adjusted thereafter to maintain serum concentrations of 150-300 ng/mL. Subsequent doses were adjusted to maintain a predefined range of trough serum concentrations of 100-250 ng/mL for up to 84 months.

| Serious adverse events | Belatacept MI | Belatacept LI | Cyclosporin A |
|---|--------------------|--------------------|--------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 162 / 183 (88.52%) | 157 / 177 (88.70%) | 152 / 179 (84.92%) |
| number of deaths (all causes) | 35 | 35 | 29 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Basal cell carcinoma | | | |
| subjects affected / exposed | 9 / 183 (4.92%) | 6 / 177 (3.39%) | 12 / 179 (6.70%) |
| occurrences causally related to treatment / all | 8 / 16 | 10 / 11 | 7 / 16 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Squamous cell carcinoma of skin | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 8 / 183 (4.37%) | 6 / 177 (3.39%) | 4 / 179 (2.23%) |
| occurrences causally related to treatment / all | 7 / 14 | 6 / 8 | 13 / 18 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostate cancer | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 4 / 177 (2.26%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 1 / 4 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bowen's disease | | | |
| subjects affected / exposed | 4 / 183 (2.19%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 5 / 5 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Kaposi's sarcoma | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 3 / 179 (1.68%) |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | 2 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| Squamous cell carcinoma | | | |
| subjects affected / exposed | 3 / 183 (1.64%) | 0 / 177 (0.00%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 2 / 3 | 0 / 0 | 2 / 2 |
| deaths causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| Central nervous system lymphoma | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 2 / 177 (1.13%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 2 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| Post transplant lymphoproliferative disorder | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 3 / 177 (1.69%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 3 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| Transitional cell carcinoma | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 1 |
| Adenocarcinoma of colon | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| B-cell lymphoma | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 1 / 1 | 0 / 0 | 1 / 1 |
| Renal cell carcinoma | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal neoplasm | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Adenocarcinoma | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| Adenocarcinoma gastric | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Breast cancer | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchial carcinoma | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| Cholangiocarcinoma | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| Colon cancer metastatic | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diffuse large B-cell lymphoma | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| Epiglottic carcinoma | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatic cancer | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Intraductal proliferative breast lesion | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Laryngeal cancer | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lipoma | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung adenocarcinoma | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| Lung cancer metastatic | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| Lung neoplasm malignant | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| Lymphoma | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| Malignant melanoma | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| Malignant pleural effusion | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastases to liver | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Myelodysplastic syndrome | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-Hodgkin's lymphoma | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-small cell lung cancer | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| Pancreatic carcinoma | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pituitary tumour benign | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pleural mesothelioma malignant | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Plasma cell myeloma | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostatic adenoma | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal adenocarcinoma | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin cancer | | | |

| | | | |
|---|-----------------|-----------------|------------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 2 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thyroid cancer | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Lymphocele | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 5 / 177 (2.82%) | 11 / 179 (6.15%) |
| occurrences causally related to treatment / all | 1 / 3 | 3 / 7 | 2 / 14 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 7 / 183 (3.83%) | 4 / 177 (2.26%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 1 / 7 | 0 / 5 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypertension | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 5 / 177 (2.82%) | 3 / 179 (1.68%) |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 5 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypotension | | | |
| subjects affected / exposed | 4 / 183 (2.19%) | 4 / 177 (2.26%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 1 / 4 | 0 / 4 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haematoma | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 3 / 177 (1.69%) | 4 / 179 (2.23%) |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 4 | 0 / 5 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypertensive crisis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 3 / 179 (1.68%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral arterial occlusive disease | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 2 / 177 (1.13%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Venous thrombosis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 3 / 177 (1.69%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arteriovenous fistula | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Extremity necrosis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral artery stenosis | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 2 / 3 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral ischaemia | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Phlebitis | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thrombophlebitis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 2 / 177 (1.13%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thrombosis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 2 / 183 (1.09%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aneurysm ruptured | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Angiopathy | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aortic aneurysm rupture | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Aortic dissection | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Aortic stenosis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arterial haemorrhage | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arterial occlusive disease | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arterial stenosis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemorrhage | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemorrhagic infarction | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypovolaemic shock | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Jugular vein thrombosis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Lymphoedema | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Shock | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Shock haemorrhagic | | | |

| | | | |
|--|------------------|------------------|------------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thrombophlebitis superficial | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular stenosis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Venous stenosis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Venous thrombosis limb | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Pyrexia | | | |
| subjects affected / exposed | 17 / 183 (9.29%) | 10 / 177 (5.65%) | 12 / 179 (6.70%) |
| occurrences causally related to treatment / all | 2 / 19 | 3 / 16 | 4 / 16 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chest pain | | | |
| subjects affected / exposed | 5 / 183 (2.73%) | 3 / 177 (1.69%) | 4 / 179 (2.23%) |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 3 | 0 / 5 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sudden death | | | |
| subjects affected / exposed | 3 / 183 (1.64%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 3 | 0 / 1 | 0 / 0 |
| Adverse drug reaction | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemorrhagic cyst | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hernia | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Incarcerated hernia | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Malaise | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Multi -organ failure | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Oedema | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Asthenia | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac death | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Cyst | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Death | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Device malfunction | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Drug intolerance | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Extravasation | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fatigue | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Impaired healing | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Influenza like illness | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Systemic inflammatory response syndrome | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ulcer haemorrhage | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| Benign prostatic hyperplasia | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 2 / 177 (1.13%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostatitis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 3 / 177 (1.69%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Acquired hydrocele | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metrorrhagia | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Priapism | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostatic obstruction | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostatism | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectocele | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Scrotal oedema | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Testicular swelling | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Uterine malposition | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vaginal haemorrhage | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 4 / 177 (2.26%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 2 | 1 / 4 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 1 / 177 (0.56%) | 5 / 179 (2.79%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 5 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| Pulmonary oedema | | | |
| subjects affected / exposed | 3 / 183 (1.64%) | 3 / 177 (1.69%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 3 | 2 / 4 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 1 / 2 | 0 / 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 2 / 177 (1.13%) | 3 / 179 (1.68%) |
| occurrences causally related to treatment / all | 0 / 1 | 2 / 2 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung disorder | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 2 / 177 (1.13%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 2 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cough | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 2 / 177 (1.13%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Acute respiratory failure | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory failure | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 2 / 177 (1.13%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Interstitial lung disease | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary hypertension | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 2 / 177 (1.13%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory distress | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Acute pulmonary oedema | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Acute respiratory distress syndrome | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aspiration | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Asthma | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchial secretion retention | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchopneumopathy | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dyspnoea paroxysmal nocturnal | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemoptysis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hiccups | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Laryngeal oedema | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mediastinal disorder | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Organising pneumonia | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Orthopnoea | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pharyngeal oedema | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary haemorrhage | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory arrest | | | |

| | | | |
|---|------------------|------------------|------------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Respiratory disorder | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vocal cord disorder | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Confusional state | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Acute psychosis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Completed suicide | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Suicide attempt | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Blood creatinine increased | | | |
| subjects affected / exposed | 14 / 183 (7.65%) | 11 / 177 (6.21%) | 17 / 179 (9.50%) |
| occurrences causally related to treatment / all | 2 / 14 | 1 / 14 | 6 / 23 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood creatine increased | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 3 / 179 (1.68%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Weight decreased | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 2 / 177 (1.13%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| White blood cell count decreased | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Antibody test positive | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood glucose abnormal | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood pressure increased | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| C-reactive protein increased | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Enterococcus test positive | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Escherichia test positive | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| International normalised ratio increased | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Liver function test abnormal | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatic enzymes increased | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Platelet count decreased | | | |

| | | | |
|---|-----------------|-----------------|------------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Polyomavirus test positive | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Weight increased | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| White blood cells urine positive | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Transplant dysfunction | | | |
| subjects affected / exposed | 9 / 183 (4.92%) | 6 / 177 (3.39%) | 11 / 179 (6.15%) |
| occurrences causally related to treatment / all | 0 / 9 | 1 / 6 | 3 / 11 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Complications of transplanted kidney | | | |
| subjects affected / exposed | 3 / 183 (1.64%) | 8 / 177 (4.52%) | 6 / 179 (3.35%) |
| occurrences causally related to treatment / all | 1 / 4 | 2 / 10 | 2 / 6 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Graft loss | | | |
| subjects affected / exposed | 4 / 183 (2.19%) | 7 / 177 (3.95%) | 6 / 179 (3.35%) |
| occurrences causally related to treatment / all | 3 / 4 | 0 / 7 | 0 / 6 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic allograft nephropathy | | | |
| subjects affected / exposed | 3 / 183 (1.64%) | 1 / 177 (0.56%) | 5 / 179 (2.79%) |
| occurrences causally related to treatment / all | 1 / 3 | 1 / 1 | 3 / 5 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Wound dehiscence | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 5 / 177 (2.82%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 5 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Incisional hernia | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 4 / 177 (2.26%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 4 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Perirenal haematoma | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 3 / 177 (1.69%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Graft thrombosis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 3 / 177 (1.69%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Wound evisceration | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 2 / 177 (1.13%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Femur fracture | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 2 / 177 (1.13%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Graft complication | | | |
| subjects affected / exposed | 3 / 183 (1.64%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 1 / 3 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Overdose | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 2 / 2 | 0 / 1 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Post procedural haematoma | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 2 / 183 (1.09%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arteriovenous fistula aneurysm | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arteriovenous fistula thrombosis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Femoral neck fracture | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Limb injury | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 3 / 177 (1.69%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Post procedural haematuria | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 2 / 177 (1.13%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Post procedural urine leak | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal transplant failure | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Shunt occlusion | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 2 / 177 (1.13%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Toxicity to various agents | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 3 / 179 (1.68%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 4 / 5 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular graft complication | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ankle fracture | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 2 / 177 (1.13%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fall | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Incorrect dose administered | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lumbar vertebral fracture | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 2 / 177 (1.13%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Meniscus injury | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Radius fracture | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Road traffic accident | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Seroma | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tendon rupture | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Transplant failure | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Acetabulum fracture | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anaemia postoperative | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anastomotic complication | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anastomotic haemorrhage | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arteriovenous fistula occlusion | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cataract operation complication | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Complications of transplant surgery | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Foot fracture | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Head injury | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Hip fracture | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Humerus fracture | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Incision site complication | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Incision site haemorrhage | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Joint dislocation | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Kidney rupture | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lower limb fracture | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Muscle rupture | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Perinephric collection | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Post procedural complication | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Post procedural haemorrhage | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Postoperative ileus | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Procedural complication | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rib fracture | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal compression fracture | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subcutaneous haematoma | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thoracic vertebral fracture | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tibia fracture | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ulna fracture | | | |

| | | | |
|---|------------------|------------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular pseudoaneurysm | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Wound | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Congenital, familial and genetic disorders | | | |
| Hydrocele | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 9 / 183 (4.92%) | 11 / 177 (6.21%) | 3 / 179 (1.68%) |
| occurrences causally related to treatment / all | 1 / 11 | 1 / 14 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac failure congestive | | | |
| subjects affected / exposed | 10 / 183 (5.46%) | 5 / 177 (2.82%) | 4 / 179 (2.23%) |
| occurrences causally related to treatment / all | 1 / 15 | 0 / 5 | 0 / 8 |
| deaths causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 0 |
| Myocardial infarction | | | |
| subjects affected / exposed | 7 / 183 (3.83%) | 3 / 177 (1.69%) | 3 / 179 (1.68%) |
| occurrences causally related to treatment / all | 0 / 8 | 0 / 3 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 1 |
| Cardiac failure | | | |
| subjects affected / exposed | 3 / 183 (1.64%) | 3 / 177 (1.69%) | 4 / 179 (2.23%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 3 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |

| | | | |
|---|-----------------|-----------------|-----------------|
| Acute myocardial infarction | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 4 / 177 (2.26%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 2 | 1 / 4 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Angina pectoris | | | |
| subjects affected / exposed | 3 / 183 (1.64%) | 1 / 177 (0.56%) | 4 / 179 (2.23%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac arrest | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 1 / 177 (0.56%) | 4 / 179 (2.23%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| Acute coronary syndrome | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 3 / 177 (1.69%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 3 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coronary artery disease | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 2 / 177 (1.13%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arteriosclerosis coronary artery | | | |
| subjects affected / exposed | 3 / 183 (1.64%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Angina unstable | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 2 / 177 (1.13%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bradycardia | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardio-respiratory arrest | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 2 |
| Arrhythmia | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Atrioventricular block | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiogenic shock | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ischaemic cardiomyopathy | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mitral valve stenosis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ventricular tachycardia | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aortic valve disease | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| Aortic valve stenosis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arrhythmia supraventricular | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial flutter | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial tachycardia | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial thrombosis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiomyopathy | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiovascular disorder | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coronary artery stenosis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intracardiac thrombus | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Left ventricular dysfunction | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myocardial ischaemia | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pericarditis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Supraventricular tachyarrhythmia | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tachyarrhythmia | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ventricular extrasystoles | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 6 / 183 (3.28%) | 1 / 177 (0.56%) | 4 / 179 (2.23%) |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 1 | 1 / 5 |
| deaths causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 2 |
| Convulsion | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 2 / 177 (1.13%) | 3 / 179 (1.68%) |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 2 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Transient ischaemic attack | | | |
| subjects affected / exposed | 3 / 183 (1.64%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ischaemic stroke | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebral haemorrhage | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Haemorrhage intracranial | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neurotoxicity | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Brain mass | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Carpal tunnel syndrome | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebellar syndrome | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Cerebral haematoma | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebral infarction | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebral ischaemia | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cognitive disorder | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Dementia | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dizziness | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Encephalitis toxic | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Epilepsy | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Guillain-Barre syndrome | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypoxic-ischaemic encephalopathy | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mononeuropathy | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Optic neuritis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Partial seizures | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Posterior reversible encephalopathy syndrome | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |

| | | | |
|---|------------------|-----------------|-----------------|
| subjects affected / exposed | 11 / 183 (6.01%) | 9 / 177 (5.08%) | 6 / 179 (3.35%) |
| occurrences causally related to treatment / all | 1 / 11 | 2 / 9 | 4 / 8 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Leukopenia | | | |
| subjects affected / exposed | 8 / 183 (4.37%) | 2 / 177 (1.13%) | 5 / 179 (2.79%) |
| occurrences causally related to treatment / all | 3 / 9 | 0 / 2 | 2 / 5 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neutropenia | | | |
| subjects affected / exposed | 3 / 183 (1.64%) | 2 / 177 (1.13%) | 3 / 179 (1.68%) |
| occurrences causally related to treatment / all | 1 / 3 | 0 / 2 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancytopenia | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 2 / 177 (1.13%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Agranulocytosis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thrombocytopenia | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Thrombotic microangiopathy | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aplasia pure red cell | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coagulopathy | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Disseminated intravascular coagulation | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Febrile neutropenia | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Granulocytopenia | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemolysis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercoagulation | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Leukocytosis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sickle cell anaemia with crisis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ear and labyrinth disorders | | | |
| Vertigo | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eye disorders | | | |
| Cataract | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eyelid ptosis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Glaucoma | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Macular fibrosis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Macular oedema | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Retinal detachment | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Retinal vein thrombosis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Uveitis | | | |

| | | | |
|---|------------------|------------------|------------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Visual acuity reduced | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Visual impairment | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Diarrhoea | | | |
| subjects affected / exposed | 18 / 183 (9.84%) | 14 / 177 (7.91%) | 10 / 179 (5.59%) |
| occurrences causally related to treatment / all | 1 / 20 | 5 / 16 | 1 / 12 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 2 / 177 (1.13%) | 6 / 179 (3.35%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 1 / 6 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal hernia | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 3 / 177 (1.69%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 1 / 177 (0.56%) | 3 / 179 (1.68%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 1 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 2 / 177 (1.13%) | 4 / 179 (2.23%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 1 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 2 / 177 (1.13%) | 3 / 179 (1.68%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Gastritis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 4 / 179 (2.23%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 1 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 2 / 177 (1.13%) | 3 / 179 (1.68%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal obstruction | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 0 / 177 (0.00%) | 3 / 179 (1.68%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Gastric ulcer | | | |
| subjects affected / exposed | 3 / 183 (1.64%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Ileus | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 2 / 177 (1.13%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lower gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestine obstruction | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 0 / 177 (0.00%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 0 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colitis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 2 / 177 (1.13%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroesophageal reflux disease | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hernial eventration | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis acute | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 2 / 177 (1.13%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Duodenal ulcer | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroduodenal ulcer | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal ischaemia | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 1 / 1 |
| Large intestine polyp | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper gastrointestinal haemorrhage | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 2 / 177 (1.13%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal distension | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain lower | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal wall haematoma | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anal fistula | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aphthous stomatitis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Constipation | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diverticular perforation | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diverticulum | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diverticulum intestinal haemorrhagic | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Duodenal perforation | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Duodenitis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dyspepsia | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Enterocolitis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Enterocolitis haemorrhagic | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Erosive oesophagitis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastric ulcer haemorrhage | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal obstruction | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal ulcer | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gingival hyperplasia | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gingival hypertrophy | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hiatus hernia | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ileus paralytic | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Impaired gastric emptying | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inguinal hernia | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal fistula | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal perforation | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestinal obstruction | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestine perforation | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Malabsorption | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophagitis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oral disorder | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peritoneal disorder | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peritoneal haemorrhage | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal prolapse | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Umbilical hernia | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Volvulus | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Cholelithiasis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 2 / 177 (1.13%) | 4 / 179 (2.23%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | 1 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholecystitis acute | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bile duct stone | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholangitis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Biliary dilatation | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholangitis acute | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholecystitis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholecystitis chronic | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholestasis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gallbladder perforation | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatic cyst | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatic mass | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatic steatosis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatitis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Skin ulcer | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 3 / 183 (1.64%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetic foot | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 2 / 177 (1.13%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 6 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Decubitus ulcer | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Angioedema | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blister | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetic bullosis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dry gangrene | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rash | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Renal failure acute | | | |

| | | | |
|---|-----------------|------------------|------------------|
| subjects affected / exposed | 7 / 183 (3.83%) | 12 / 177 (6.78%) | 11 / 179 (6.15%) |
| occurrences causally related to treatment / all | 1 / 17 | 1 / 12 | 2 / 14 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal artery stenosis | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 5 / 177 (2.82%) | 7 / 179 (3.91%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 5 | 0 / 8 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal impairment | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 3 / 177 (1.69%) | 9 / 179 (5.03%) |
| occurrences causally related to treatment / all | 1 / 2 | 1 / 3 | 2 / 11 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ureteric stenosis | | | |
| subjects affected / exposed | 4 / 183 (2.19%) | 3 / 177 (1.69%) | 4 / 179 (2.23%) |
| occurrences causally related to treatment / all | 0 / 9 | 0 / 5 | 0 / 8 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haematuria | | | |
| subjects affected / exposed | 4 / 183 (2.19%) | 2 / 177 (1.13%) | 3 / 179 (1.68%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 2 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal tubular necrosis | | | |
| subjects affected / exposed | 4 / 183 (2.19%) | 3 / 177 (1.69%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 1 / 4 | 0 / 3 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal vein thrombosis | | | |
| subjects affected / exposed | 6 / 183 (3.28%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 6 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary fistula | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 6 / 179 (3.35%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 7 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydronephrosis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 2 / 183 (1.09%) | 1 / 177 (0.56%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nephrolithiasis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 2 / 177 (1.13%) | 3 / 179 (1.68%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Obstructive uropathy | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Proteinuria | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal cyst | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 3 / 179 (1.68%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 1 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 0 / 177 (0.00%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary incontinence | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 3 / 179 (1.68%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nephropathy | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal artery thrombosis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal haemorrhage | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal tubular disorder | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 2 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urethral stenosis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 2 / 177 (1.13%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vesicoureteric reflux | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bladder prolapse | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nephropathy toxic | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal infarct | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract obstruction | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Azotaemia | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bladder neck sclerosis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bladder obstruction | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetic nephropathy | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dysuria | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypertonic bladder | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Microalbuminuria | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nephritis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nephrotic syndrome | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Perinephric effusion | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Postrenal failure | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prerenal failure | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyelocaliectasis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal artery dissection | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal cyst haemorrhage | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure chronic | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal tubular atrophy | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ureteral necrosis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ureteric dilatation | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ureteric fistula | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ureteric obstruction | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urethral disorder | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urethral obstruction | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urine abnormality | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vesical fistula | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endocrine disorders | | | |
| Adrenal mass | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| Hyperparathyroidism | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperparathyroidism tertiary | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperthyroidism | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthritis | | | |
| subjects affected / exposed | 3 / 183 (1.64%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|-----------------|-----------------|
| Arthralgia | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Back pain | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Osteoarthritis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Muscle haemorrhage | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Osteitis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Osteonecrosis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bursitis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diastasis recti abdominis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dupuytren's contracture | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fistula | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercreatinaemia | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intervertebral disc disorder | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intervertebral disc protrusion | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Joint effusion | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mobility decreased | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myopathy | | | |

| | | | |
|---|-------------------|-------------------|-------------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neck pain | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Post transplant distal limb syndrome | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rotator cuff syndrome | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Synovitis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tenosynovitis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Urinary tract infection | | | |
| subjects affected / exposed | 25 / 183 (13.66%) | 28 / 177 (15.82%) | 26 / 179 (14.53%) |
| occurrences causally related to treatment / all | 8 / 39 | 6 / 36 | 9 / 47 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cytomegalovirus infection | | | |

| | | | |
|---|------------------|------------------|------------------|
| subjects affected / exposed | 18 / 183 (9.84%) | 16 / 177 (9.04%) | 13 / 179 (7.26%) |
| occurrences causally related to treatment / all | 17 / 29 | 10 / 18 | 4 / 13 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 15 / 183 (8.20%) | 14 / 177 (7.91%) | 11 / 179 (6.15%) |
| occurrences causally related to treatment / all | 6 / 21 | 8 / 20 | 4 / 13 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 2 |
| Sepsis | | | |
| subjects affected / exposed | 8 / 183 (4.37%) | 10 / 177 (5.65%) | 15 / 179 (8.38%) |
| occurrences causally related to treatment / all | 1 / 10 | 2 / 10 | 4 / 16 |
| deaths causally related to treatment / all | 0 / 4 | 0 / 3 | 2 / 4 |
| Pyelonephritis | | | |
| subjects affected / exposed | 12 / 183 (6.56%) | 6 / 177 (3.39%) | 14 / 179 (7.82%) |
| occurrences causally related to treatment / all | 4 / 17 | 3 / 6 | 2 / 21 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Gastroenteritis | | | |
| subjects affected / exposed | 8 / 183 (4.37%) | 6 / 177 (3.39%) | 8 / 179 (4.47%) |
| occurrences causally related to treatment / all | 1 / 8 | 2 / 6 | 1 / 8 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |
| subjects affected / exposed | 6 / 183 (3.28%) | 7 / 177 (3.95%) | 6 / 179 (3.35%) |
| occurrences causally related to treatment / all | 2 / 8 | 1 / 7 | 3 / 8 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| Herpes zoster | | | |
| subjects affected / exposed | 8 / 183 (4.37%) | 3 / 177 (1.69%) | 3 / 179 (1.68%) |
| occurrences causally related to treatment / all | 3 / 8 | 1 / 3 | 1 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyelonephritis acute | | | |
| subjects affected / exposed | 4 / 183 (2.19%) | 1 / 177 (0.56%) | 7 / 179 (3.91%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 1 | 0 / 13 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Septic shock | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 2 / 183 (1.09%) | 2 / 177 (1.13%) | 6 / 179 (3.35%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 1 / 7 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 2 | 1 / 5 |
| Bacteraemia | | | |
| subjects affected / exposed | 3 / 183 (1.64%) | 1 / 177 (0.56%) | 5 / 179 (2.79%) |
| occurrences causally related to treatment / all | 2 / 3 | 0 / 1 | 0 / 6 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchitis | | | |
| subjects affected / exposed | 3 / 183 (1.64%) | 3 / 177 (1.69%) | 3 / 179 (1.68%) |
| occurrences causally related to treatment / all | 1 / 3 | 0 / 3 | 2 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cellulitis | | | |
| subjects affected / exposed | 5 / 183 (2.73%) | 4 / 177 (2.26%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 2 / 5 | 1 / 5 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Escherichia urinary tract infection | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 1 / 177 (0.56%) | 5 / 179 (2.79%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | 2 / 5 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory tract infection | | | |
| subjects affected / exposed | 3 / 183 (1.64%) | 3 / 177 (1.69%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 3 / 4 | 2 / 4 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection bacterial | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 3 / 177 (1.69%) | 3 / 179 (1.68%) |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 3 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gangrene | | | |
| subjects affected / exposed | 4 / 183 (2.19%) | 2 / 177 (1.13%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Osteomyelitis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 4 / 183 (2.19%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 2 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Pneumocystis jirovecii pneumonia | | | |
| subjects affected / exposed | 3 / 183 (1.64%) | 2 / 177 (1.13%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 2 / 3 | 2 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Postoperative wound infection | | | |
| subjects affected / exposed | 3 / 183 (1.64%) | 2 / 177 (1.13%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 3 | 1 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sinusitis | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 1 / 177 (0.56%) | 3 / 179 (1.68%) |
| occurrences causally related to treatment / all | 1 / 2 | 2 / 2 | 2 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection pseudomonal | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 3 / 177 (1.69%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 2 / 4 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abscess | | | |
| subjects affected / exposed | 3 / 183 (1.64%) | 0 / 177 (0.00%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 2 / 3 | 0 / 0 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchopneumonia | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 4 / 177 (2.26%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 4 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| Device related infection | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 1 / 177 (0.56%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 1 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatic cyst infection | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 3 / 179 (1.68%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Polyomavirus-associated nephropathy | | | |
| subjects affected / exposed | 3 / 183 (1.64%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 1 / 3 | 1 / 1 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| Wound infection | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 1 / 177 (0.56%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 2 / 2 | 1 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 2 / 177 (1.13%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Clostridium difficile colitis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 2 / 177 (1.13%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cryptococcosis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 3 / 177 (1.69%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Cytomegalovirus viraemia | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 3 / 179 (1.68%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 3 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diverticulitis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis viral | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 2 / 183 (1.09%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Meningitis cryptococcal | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 2 / 177 (1.13%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 2 | 2 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 1 / 1 | 0 / 0 |
| Pseudomonal sepsis | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 1 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary tuberculosis | | | |
| subjects affected / exposed | 3 / 183 (1.64%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 3 / 3 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abscess limb | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Appendicitis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 2 / 177 (1.13%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacterial pyelonephritis | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cytomegalovirus colitis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | 2 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal cyst infection | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 5 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Transplant abscess | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 2 / 177 (1.13%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection enterococcal | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 2 / 177 (1.13%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal abscess | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 2 / 2 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aspergillus infection | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetic gangrene | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Disseminated tuberculosis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 2 / 177 (1.13%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Endocarditis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Enterobacter infection | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 2 / 177 (1.13%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Enterococcal bacteraemia | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Epididymitis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Erysipelas | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Escherichia bacteraemia | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Escherichia sepsis | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Helicobacter gastritis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatitis B | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infected lymphocele | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Localised infection | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Necrotising fasciitis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Pneumonia klebsiella | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Staphylococcal bacteraemia | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Strongyloidiasis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 2 / 177 (1.13%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 3 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tracheobronchitis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 2 / 177 (1.13%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Viral infection | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abscess rupture | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anal abscess | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Appendicitis perforated | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Asymptomatic bacteriuria | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| BK virus infection | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacterial infection | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacterial prostatitis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebral aspergillosis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebral fungal infection | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| Chorioretinitis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Clostridium difficile infection | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cystitis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cystitis bacterial | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cytomegalovirus chorioretinitis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cytomegalovirus enteritis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cytomegalovirus gastritis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cytomegalovirus gastroenteritis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cytomegalovirus gastrointestinal infection | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cytomegalovirus hepatitis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cytomegalovirus syndrome | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Device related sepsis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea infectious | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Disseminated cytomegaloviral infection | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dysentery | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Emphysematous cystitis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Encephalomyelitis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| Endocarditis bacterial | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Enterococcal infection | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fungal infection | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Helicobacter infection | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Herpes zoster disseminated | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Human polyomavirus infection | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Incision site infection | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infected cyst | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infectious pleural effusion | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Joint tuberculosis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Kidney infection | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Klebsiella infection | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Leishmaniasis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lobar pneumonia | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung infection | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Lymphangitis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mycoplasma infection | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophageal candidiasis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oral candidiasis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oral fungal infection | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Perirectal abscess | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia bacterial | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia cryptococcal | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia cytomegaloviral | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia fungal | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Progressive multifocal leukoencephalopathy | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| Pseudomonas infection | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psoas abscess | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Purulent discharge | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory tract infection fungal | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sinusitis bacterial | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Staphylococcal infection | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Staphylococcal sepsis | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tooth abscess | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tuberculosis | | | |

| | | | |
|---|-----------------|------------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tuberculosis of eye | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tuberculosis laryngitis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Varicella | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 7 / 183 (3.83%) | 10 / 177 (5.65%) | 6 / 179 (3.35%) |
| occurrences causally related to treatment / all | 1 / 7 | 2 / 11 | 0 / 6 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 3 / 183 (1.64%) | 4 / 177 (2.26%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 6 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 3 / 177 (1.69%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 1 / 2 | 1 / 3 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 1 / 177 (0.56%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetes mellitus | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fluid overload | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypocalcaemia | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 2 / 177 (1.13%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gout | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 2 / 183 (1.09%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypovolaemia | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolic acidosis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Type 1 diabetes mellitus | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 2 / 179 (1.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cachexia | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Decreased appetite | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetic ketoacidosis | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrolyte imbalance | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 0 / 177 (0.00%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercreatininaemia | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Iron deficiency | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 1 / 179 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Obesity | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 0 / 179 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Belatacept MI | Belatacept LI | Cyclosporin A |
|--|--------------------|--------------------|---------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 177 / 183 (96.72%) | 171 / 177 (96.61%) | 179 / 179 (100.00%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Skin papilloma | | | |
| subjects affected / exposed | 11 / 183 (6.01%) | 6 / 177 (3.39%) | 11 / 179 (6.15%) |
| occurrences (all) | 23 | 7 | 22 |
| Vascular disorders | | | |
| Hypertension | | | |
| subjects affected / exposed | 63 / 183 (34.43%) | 63 / 177 (35.59%) | 80 / 179 (44.69%) |
| occurrences (all) | 131 | 170 | 190 |
| Hypotension | | | |
| subjects affected / exposed | 38 / 183 (20.77%) | 52 / 177 (29.38%) | 29 / 179 (16.20%) |
| occurrences (all) | 69 | 86 | 54 |
| Haematoma | | | |
| subjects affected / exposed | 16 / 183 (8.74%) | 16 / 177 (9.04%) | 18 / 179 (10.06%) |
| occurrences (all) | 27 | 22 | 23 |
| Lymphocele | | | |
| subjects affected / exposed | 9 / 183 (4.92%) | 7 / 177 (3.95%) | 15 / 179 (8.38%) |
| occurrences (all) | 18 | 20 | 42 |
| General disorders and administration site conditions | | | |
| Oedema peripheral | | | |
| subjects affected / exposed | 92 / 183 (50.27%) | 81 / 177 (45.76%) | 96 / 179 (53.63%) |
| occurrences (all) | 295 | 269 | 412 |
| Pyrexia | | | |

| | | | |
|---|-------------------|-------------------|-------------------|
| subjects affected / exposed | 56 / 183 (30.60%) | 64 / 177 (36.16%) | 52 / 179 (29.05%) |
| occurrences (all) | 98 | 107 | 112 |
| Oedema | | | |
| subjects affected / exposed | 26 / 183 (14.21%) | 23 / 177 (12.99%) | 30 / 179 (16.76%) |
| occurrences (all) | 65 | 68 | 51 |
| Chest pain | | | |
| subjects affected / exposed | 22 / 183 (12.02%) | 24 / 177 (13.56%) | 24 / 179 (13.41%) |
| occurrences (all) | 34 | 42 | 46 |
| Fatigue | | | |
| subjects affected / exposed | 26 / 183 (14.21%) | 22 / 177 (12.43%) | 19 / 179 (10.61%) |
| occurrences (all) | 41 | 44 | 39 |
| Asthenia | | | |
| subjects affected / exposed | 23 / 183 (12.57%) | 17 / 177 (9.60%) | 23 / 179 (12.85%) |
| occurrences (all) | 42 | 35 | 53 |
| Pain | | | |
| subjects affected / exposed | 13 / 183 (7.10%) | 13 / 177 (7.34%) | 14 / 179 (7.82%) |
| occurrences (all) | 29 | 15 | 31 |
| Peripheral swelling | | | |
| subjects affected / exposed | 10 / 183 (5.46%) | 14 / 177 (7.91%) | 12 / 179 (6.70%) |
| occurrences (all) | 24 | 31 | 23 |
| Chills | | | |
| subjects affected / exposed | 9 / 183 (4.92%) | 6 / 177 (3.39%) | 9 / 179 (5.03%) |
| occurrences (all) | 11 | 8 | 10 |
| Reproductive system and breast disorders | | | |
| Erectile dysfunction | | | |
| subjects affected / exposed | 12 / 183 (6.56%) | 9 / 177 (5.08%) | 5 / 179 (2.79%) |
| occurrences (all) | 18 | 14 | 6 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 53 / 183 (28.96%) | 56 / 177 (31.64%) | 41 / 179 (22.91%) |
| occurrences (all) | 155 | 138 | 103 |
| Dyspnoea | | | |
| subjects affected / exposed | 33 / 183 (18.03%) | 40 / 177 (22.60%) | 37 / 179 (20.67%) |
| occurrences (all) | 67 | 90 | 85 |
| Oropharyngeal pain | | | |

| | | | |
|--|-------------------------|-------------------------|-------------------------|
| subjects affected / exposed occurrences (all) | 16 / 183 (8.74%) 26 | 9 / 177 (5.08%) 17 | 11 / 179 (6.15%) 13 |
| Dyspnoea exertional subjects affected / exposed occurrences (all) | 15 / 183 (8.20%) 27 | 10 / 177 (5.65%) 20 | 8 / 179 (4.47%) 22 |
| Productive cough subjects affected / exposed occurrences (all) | 9 / 183 (4.92%) 18 | 18 / 177 (10.17%) 36 | 6 / 179 (3.35%) 12 |
| Nasal congestion subjects affected / exposed occurrences (all) | 5 / 183 (2.73%) 7 | 1 / 177 (0.56%) 1 | 9 / 179 (5.03%) 12 |
| Psychiatric disorders | | | |
| Insomnia subjects affected / exposed occurrences (all) | 37 / 183 (20.22%) 92 | 31 / 177 (17.51%) 56 | 39 / 179 (21.79%) 77 |
| Anxiety subjects affected / exposed occurrences (all) | 27 / 183 (14.75%) 55 | 20 / 177 (11.30%) 33 | 30 / 179 (16.76%) 48 |
| Depression subjects affected / exposed occurrences (all) | 8 / 183 (4.37%) 22 | 16 / 177 (9.04%) 43 | 18 / 179 (10.06%) 30 |
| Investigations | | | |
| Blood creatinine increased subjects affected / exposed occurrences (all) | 29 / 183 (15.85%) 63 | 29 / 177 (16.38%) 71 | 31 / 179 (17.32%) 71 |
| Weight decreased subjects affected / exposed occurrences (all) | 17 / 183 (9.29%) 32 | 21 / 177 (11.86%) 45 | 13 / 179 (7.26%) 20 |
| Weight increased subjects affected / exposed occurrences (all) | 15 / 183 (8.20%) 30 | 13 / 177 (7.34%) 24 | 11 / 179 (6.15%) 18 |
| C-reactive protein increased subjects affected / exposed occurrences (all) | 12 / 183 (6.56%) 30 | 14 / 177 (7.91%) 36 | 11 / 179 (6.15%) 22 |
| Blood pressure increased | | | |

| | | | |
|--|-----------------------|----------------------|------------------------|
| subjects affected / exposed occurrences (all) | 8 / 183 (4.37%) 12 | 5 / 177 (2.82%) 8 | 10 / 179 (5.59%) 16 |
| Injury, poisoning and procedural complications | | | |
| Transplant dysfunction | | | |
| subjects affected / exposed | 65 / 183 (35.52%) | 64 / 177 (36.16%) | 85 / 179 (47.49%) |
| occurrences (all) | 129 | 117 | 176 |
| Procedural pain | | | |
| subjects affected / exposed | 36 / 183 (19.67%) | 38 / 177 (21.47%) | 37 / 179 (20.67%) |
| occurrences (all) | 74 | 59 | 62 |
| Incision site pain | | | |
| subjects affected / exposed | 26 / 183 (14.21%) | 22 / 177 (12.43%) | 36 / 179 (20.11%) |
| occurrences (all) | 52 | 43 | 71 |
| Complications of transplanted kidney | | | |
| subjects affected / exposed | 10 / 183 (5.46%) | 20 / 177 (11.30%) | 17 / 179 (9.50%) |
| occurrences (all) | 14 | 39 | 42 |
| Chronic allograft nephropathy | | | |
| subjects affected / exposed | 14 / 183 (7.65%) | 9 / 177 (5.08%) | 22 / 179 (12.29%) |
| occurrences (all) | 21 | 11 | 23 |
| Fall | | | |
| subjects affected / exposed | 16 / 183 (8.74%) | 8 / 177 (4.52%) | 11 / 179 (6.15%) |
| occurrences (all) | 23 | 12 | 18 |
| Contusion | | | |
| subjects affected / exposed | 8 / 183 (4.37%) | 11 / 177 (6.21%) | 4 / 179 (2.23%) |
| occurrences (all) | 21 | 19 | 13 |
| Arteriovenous fistula thrombosis | | | |
| subjects affected / exposed | 4 / 183 (2.19%) | 7 / 177 (3.95%) | 9 / 179 (5.03%) |
| occurrences (all) | 5 | 10 | 14 |
| Toxicity to various agents | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 1 / 177 (0.56%) | 18 / 179 (10.06%) |
| occurrences (all) | 1 | 1 | 27 |
| Ligament sprain | | | |
| subjects affected / exposed | 8 / 183 (4.37%) | 1 / 177 (0.56%) | 10 / 179 (5.59%) |
| occurrences (all) | 14 | 2 | 16 |
| Wound dehiscence | | | |

| | | | |
|------------------------------|-------------------|-------------------|-------------------|
| subjects affected / exposed | 3 / 183 (1.64%) | 5 / 177 (2.82%) | 10 / 179 (5.59%) |
| occurrences (all) | 14 | 14 | 17 |
| Wound complication | | | |
| subjects affected / exposed | 3 / 183 (1.64%) | 5 / 177 (2.82%) | 9 / 179 (5.03%) |
| occurrences (all) | 4 | 9 | 14 |
| Post procedural discharge | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 2 / 177 (1.13%) | 9 / 179 (5.03%) |
| occurrences (all) | 1 | 2 | 15 |
| Cardiac disorders | | | |
| Tachycardia | | | |
| subjects affected / exposed | 14 / 183 (7.65%) | 22 / 177 (12.43%) | 12 / 179 (6.70%) |
| occurrences (all) | 17 | 47 | 24 |
| Atrial fibrillation | | | |
| subjects affected / exposed | 16 / 183 (8.74%) | 11 / 177 (6.21%) | 12 / 179 (6.70%) |
| occurrences (all) | 27 | 28 | 21 |
| Bradycardia | | | |
| subjects affected / exposed | 10 / 183 (5.46%) | 7 / 177 (3.95%) | 12 / 179 (6.70%) |
| occurrences (all) | 13 | 14 | 18 |
| Angina pectoris | | | |
| subjects affected / exposed | 5 / 183 (2.73%) | 8 / 177 (4.52%) | 12 / 179 (6.70%) |
| occurrences (all) | 7 | 10 | 15 |
| Sinus bradycardia | | | |
| subjects affected / exposed | 8 / 183 (4.37%) | 4 / 177 (2.26%) | 9 / 179 (5.03%) |
| occurrences (all) | 9 | 6 | 11 |
| Left ventricular hypertrophy | | | |
| subjects affected / exposed | 5 / 183 (2.73%) | 9 / 177 (5.08%) | 6 / 179 (3.35%) |
| occurrences (all) | 7 | 12 | 11 |
| Nervous system disorders | | | |
| Headache | | | |
| subjects affected / exposed | 37 / 183 (20.22%) | 41 / 177 (23.16%) | 47 / 179 (26.26%) |
| occurrences (all) | 95 | 108 | 110 |
| Tremor | | | |
| subjects affected / exposed | 17 / 183 (9.29%) | 21 / 177 (11.86%) | 31 / 179 (17.32%) |
| occurrences (all) | 29 | 38 | 56 |
| Dizziness | | | |

| | | | |
|--|--------------------------|--------------------------|---------------------------|
| subjects affected / exposed occurrences (all) | 26 / 183 (14.21%) 47 | 18 / 177 (10.17%) 32 | 18 / 179 (10.06%) 33 |
| Paraesthesia subjects affected / exposed occurrences (all) | 11 / 183 (6.01%) 17 | 13 / 177 (7.34%) 23 | 16 / 179 (8.94%) 37 |
| Sciatica subjects affected / exposed occurrences (all) | 7 / 183 (3.83%) 10 | 11 / 177 (6.21%) 22 | 8 / 179 (4.47%) 11 |
| Blood and lymphatic system disorders | | | |
| Anaemia subjects affected / exposed occurrences (all) | 98 / 183 (53.55%) 286 | 93 / 177 (52.54%) 281 | 103 / 179 (57.54%) 270 |
| Leukopenia subjects affected / exposed occurrences (all) | 51 / 183 (27.87%) 135 | 40 / 177 (22.60%) 86 | 48 / 179 (26.82%) 126 |
| Thrombocytopenia subjects affected / exposed occurrences (all) | 24 / 183 (13.11%) 48 | 13 / 177 (7.34%) 29 | 11 / 179 (6.15%) 30 |
| Leukocytosis subjects affected / exposed occurrences (all) | 15 / 183 (8.20%) 32 | 12 / 177 (6.78%) 14 | 9 / 179 (5.03%) 18 |
| Neutropenia subjects affected / exposed occurrences (all) | 12 / 183 (6.56%) 20 | 10 / 177 (5.65%) 21 | 12 / 179 (6.70%) 27 |
| Lymphopenia subjects affected / exposed occurrences (all) | 10 / 183 (5.46%) 23 | 12 / 177 (6.78%) 20 | 8 / 179 (4.47%) 15 |
| Polycythaemia subjects affected / exposed occurrences (all) | 4 / 183 (2.19%) 15 | 10 / 177 (5.65%) 17 | 7 / 179 (3.91%) 15 |
| Ear and labyrinth disorders | | | |
| Vertigo subjects affected / exposed occurrences (all) | 5 / 183 (2.73%) 7 | 14 / 177 (7.91%) 19 | 8 / 179 (4.47%) 13 |
| Eye disorders | | | |

| | | | |
|----------------------------------|--------------------|-------------------|-------------------|
| Cataract | | | |
| subjects affected / exposed | 20 / 183 (10.93%) | 13 / 177 (7.34%) | 16 / 179 (8.94%) |
| occurrences (all) | 27 | 21 | 34 |
| Gastrointestinal disorders | | | |
| Diarrhoea | | | |
| subjects affected / exposed | 103 / 183 (56.28%) | 94 / 177 (53.11%) | 74 / 179 (41.34%) |
| occurrences (all) | 358 | 304 | 196 |
| Constipation | | | |
| subjects affected / exposed | 61 / 183 (33.33%) | 63 / 177 (35.59%) | 79 / 179 (44.13%) |
| occurrences (all) | 149 | 132 | 177 |
| Nausea | | | |
| subjects affected / exposed | 54 / 183 (29.51%) | 49 / 177 (27.68%) | 52 / 179 (29.05%) |
| occurrences (all) | 113 | 95 | 98 |
| Vomiting | | | |
| subjects affected / exposed | 37 / 183 (20.22%) | 51 / 177 (28.81%) | 44 / 179 (24.58%) |
| occurrences (all) | 64 | 87 | 88 |
| Abdominal pain | | | |
| subjects affected / exposed | 30 / 183 (16.39%) | 39 / 177 (22.03%) | 33 / 179 (18.44%) |
| occurrences (all) | 55 | 75 | 66 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 21 / 183 (11.48%) | 25 / 177 (14.12%) | 27 / 179 (15.08%) |
| occurrences (all) | 37 | 43 | 55 |
| Dyspepsia | | | |
| subjects affected / exposed | 22 / 183 (12.02%) | 16 / 177 (9.04%) | 20 / 179 (11.17%) |
| occurrences (all) | 38 | 29 | 29 |
| Abdominal distension | | | |
| subjects affected / exposed | 13 / 183 (7.10%) | 13 / 177 (7.34%) | 19 / 179 (10.61%) |
| occurrences (all) | 25 | 20 | 34 |
| Haemorrhoids | | | |
| subjects affected / exposed | 16 / 183 (8.74%) | 13 / 177 (7.34%) | 8 / 179 (4.47%) |
| occurrences (all) | 31 | 30 | 12 |
| Aphthous stomatitis | | | |
| subjects affected / exposed | 10 / 183 (5.46%) | 13 / 177 (7.34%) | 4 / 179 (2.23%) |
| occurrences (all) | 31 | 33 | 6 |
| Gastrooesophageal reflux disease | | | |

| | | | |
|--|-------------------|-------------------|-------------------|
| subjects affected / exposed | 9 / 183 (4.92%) | 9 / 177 (5.08%) | 9 / 179 (5.03%) |
| occurrences (all) | 9 | 12 | 12 |
| Gastritis | | | |
| subjects affected / exposed | 8 / 183 (4.37%) | 7 / 177 (3.95%) | 9 / 179 (5.03%) |
| occurrences (all) | 15 | 19 | 12 |
| Flatulence | | | |
| subjects affected / exposed | 5 / 183 (2.73%) | 5 / 177 (2.82%) | 10 / 179 (5.59%) |
| occurrences (all) | 13 | 9 | 17 |
| Gingival hypertrophy | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 1 / 177 (0.56%) | 9 / 179 (5.03%) |
| occurrences (all) | 0 | 1 | 22 |
| Gingival hyperplasia | | | |
| subjects affected / exposed | 0 / 183 (0.00%) | 0 / 177 (0.00%) | 9 / 179 (5.03%) |
| occurrences (all) | 0 | 0 | 20 |
| Skin and subcutaneous tissue disorders | | | |
| Skin lesion | | | |
| subjects affected / exposed | 18 / 183 (9.84%) | 15 / 177 (8.47%) | 11 / 179 (6.15%) |
| occurrences (all) | 35 | 28 | 18 |
| Acne | | | |
| subjects affected / exposed | 7 / 183 (3.83%) | 12 / 177 (6.78%) | 15 / 179 (8.38%) |
| occurrences (all) | 16 | 24 | 34 |
| Pruritus | | | |
| subjects affected / exposed | 16 / 183 (8.74%) | 8 / 177 (4.52%) | 6 / 179 (3.35%) |
| occurrences (all) | 26 | 9 | 10 |
| Ecchymosis | | | |
| subjects affected / exposed | 13 / 183 (7.10%) | 4 / 177 (2.26%) | 9 / 179 (5.03%) |
| occurrences (all) | 30 | 8 | 15 |
| Hyperkeratosis | | | |
| subjects affected / exposed | 8 / 183 (4.37%) | 9 / 177 (5.08%) | 5 / 179 (2.79%) |
| occurrences (all) | 16 | 15 | 9 |
| Renal and urinary disorders | | | |
| Haematuria | | | |
| subjects affected / exposed | 41 / 183 (22.40%) | 39 / 177 (22.03%) | 36 / 179 (20.11%) |
| occurrences (all) | 88 | 89 | 69 |
| Proteinuria | | | |

| | | | |
|---|-------------------|-------------------|-------------------|
| subjects affected / exposed | 40 / 183 (21.86%) | 36 / 177 (20.34%) | 29 / 179 (16.20%) |
| occurrences (all) | 89 | 90 | 75 |
| Renal tubular necrosis | | | |
| subjects affected / exposed | 17 / 183 (9.29%) | 21 / 177 (11.86%) | 30 / 179 (16.76%) |
| occurrences (all) | 29 | 34 | 78 |
| Dysuria | | | |
| subjects affected / exposed | 25 / 183 (13.66%) | 23 / 177 (12.99%) | 16 / 179 (8.94%) |
| occurrences (all) | 53 | 36 | 26 |
| Renal impairment | | | |
| subjects affected / exposed | 13 / 183 (7.10%) | 13 / 177 (7.34%) | 19 / 179 (10.61%) |
| occurrences (all) | 25 | 25 | 41 |
| Leukocyturia | | | |
| subjects affected / exposed | 13 / 183 (7.10%) | 14 / 177 (7.91%) | 12 / 179 (6.70%) |
| occurrences (all) | 53 | 41 | 58 |
| Hydronephrosis | | | |
| subjects affected / exposed | 9 / 183 (4.92%) | 2 / 177 (1.13%) | 11 / 179 (6.15%) |
| occurrences (all) | 11 | 3 | 18 |
| Urinary retention | | | |
| subjects affected / exposed | 5 / 183 (2.73%) | 6 / 177 (3.39%) | 11 / 179 (6.15%) |
| occurrences (all) | 8 | 8 | 23 |
| Renal failure acute | | | |
| subjects affected / exposed | 4 / 183 (2.19%) | 7 / 177 (3.95%) | 9 / 179 (5.03%) |
| occurrences (all) | 4 | 11 | 12 |
| Endocrine disorders | | | |
| Hyperparathyroidism | | | |
| subjects affected / exposed | 7 / 183 (3.83%) | 5 / 177 (2.82%) | 12 / 179 (6.70%) |
| occurrences (all) | 10 | 5 | 17 |
| Cushingoid | | | |
| subjects affected / exposed | 6 / 183 (3.28%) | 7 / 177 (3.95%) | 9 / 179 (5.03%) |
| occurrences (all) | 8 | 11 | 13 |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 41 / 183 (22.40%) | 44 / 177 (24.86%) | 39 / 179 (21.79%) |
| occurrences (all) | 100 | 98 | 81 |
| Pain in extremity | | | |

| | | | |
|-----------------------------|-------------------|-------------------|-------------------|
| subjects affected / exposed | 35 / 183 (19.13%) | 34 / 177 (19.21%) | 42 / 179 (23.46%) |
| occurrences (all) | 78 | 69 | 116 |
| Arthralgia | | | |
| subjects affected / exposed | 33 / 183 (18.03%) | 43 / 177 (24.29%) | 34 / 179 (18.99%) |
| occurrences (all) | 76 | 97 | 77 |
| Muscle spasms | | | |
| subjects affected / exposed | 17 / 183 (9.29%) | 17 / 177 (9.60%) | 19 / 179 (10.61%) |
| occurrences (all) | 28 | 38 | 34 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 13 / 183 (7.10%) | 15 / 177 (8.47%) | 10 / 179 (5.59%) |
| occurrences (all) | 22 | 34 | 14 |
| Myalgia | | | |
| subjects affected / exposed | 11 / 183 (6.01%) | 9 / 177 (5.08%) | 17 / 179 (9.50%) |
| occurrences (all) | 19 | 13 | 26 |
| Osteoporosis | | | |
| subjects affected / exposed | 13 / 183 (7.10%) | 7 / 177 (3.95%) | 5 / 179 (2.79%) |
| occurrences (all) | 17 | 18 | 5 |
| Osteopenia | | | |
| subjects affected / exposed | 10 / 183 (5.46%) | 7 / 177 (3.95%) | 6 / 179 (3.35%) |
| occurrences (all) | 12 | 7 | 12 |
| Neck pain | | | |
| subjects affected / exposed | 5 / 183 (2.73%) | 5 / 177 (2.82%) | 9 / 179 (5.03%) |
| occurrences (all) | 6 | 7 | 13 |
| Muscular weakness | | | |
| subjects affected / exposed | 4 / 183 (2.19%) | 4 / 177 (2.26%) | 10 / 179 (5.59%) |
| occurrences (all) | 7 | 6 | 14 |
| Infections and infestations | | | |
| Urinary tract infection | | | |
| subjects affected / exposed | 79 / 183 (43.17%) | 76 / 177 (42.94%) | 86 / 179 (48.04%) |
| occurrences (all) | 364 | 293 | 347 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 45 / 183 (24.59%) | 44 / 177 (24.86%) | 38 / 179 (21.23%) |
| occurrences (all) | 135 | 139 | 99 |
| Bronchitis | | | |
| subjects affected / exposed | 37 / 183 (20.22%) | 36 / 177 (20.34%) | 25 / 179 (13.97%) |
| occurrences (all) | 83 | 84 | 57 |

| | | | |
|---|--------------------------|-------------------------|-------------------------|
| Cytomegalovirus infection subjects affected / exposed occurrences (all) | 22 / 183 (12.02%) 82 | 18 / 177 (10.17%) 64 | 17 / 179 (9.50%) 41 |
| Upper respiratory tract infection subjects affected / exposed occurrences (all) | 35 / 183 (19.13%) 108 | 29 / 177 (16.38%) 96 | 23 / 179 (12.85%) 81 |
| Sinusitis subjects affected / exposed occurrences (all) | 19 / 183 (10.38%) 48 | 23 / 177 (12.99%) 51 | 20 / 179 (11.17%) 58 |
| Herpes zoster subjects affected / exposed occurrences (all) | 21 / 183 (11.48%) 47 | 17 / 177 (9.60%) 34 | 13 / 179 (7.26%) 21 |
| Influenza subjects affected / exposed occurrences (all) | 17 / 183 (9.29%) 30 | 16 / 177 (9.04%) 38 | 18 / 179 (10.06%) 29 |
| Gastroenteritis subjects affected / exposed occurrences (all) | 8 / 183 (4.37%) 13 | 18 / 177 (10.17%) 26 | 22 / 179 (12.29%) 29 |
| Oral candidiasis subjects affected / exposed occurrences (all) | 14 / 183 (7.65%) 31 | 10 / 177 (5.65%) 27 | 13 / 179 (7.26%) 22 |
| Oral herpes subjects affected / exposed occurrences (all) | 13 / 183 (7.10%) 34 | 14 / 177 (7.91%) 26 | 9 / 179 (5.03%) 18 |
| Pneumonia subjects affected / exposed occurrences (all) | 7 / 183 (3.83%) 9 | 15 / 177 (8.47%) 21 | 11 / 179 (6.15%) 18 |
| Conjunctivitis subjects affected / exposed occurrences (all) | 15 / 183 (8.20%) 25 | 9 / 177 (5.08%) 17 | 7 / 179 (3.91%) 11 |
| Rhinitis subjects affected / exposed occurrences (all) | 11 / 183 (6.01%) 14 | 8 / 177 (4.52%) 12 | 11 / 179 (6.15%) 18 |
| Escherichia urinary tract infection subjects affected / exposed occurrences (all) | 9 / 183 (4.92%) 47 | 6 / 177 (3.39%) 11 | 13 / 179 (7.26%) 25 |

| | | | |
|---|--------------------------|-------------------------|--------------------------|
| Onychomycosis subjects affected / exposed occurrences (all) | 14 / 183 (7.65%) 33 | 6 / 177 (3.39%) 9 | 8 / 179 (4.47%) 14 |
| Fungal skin infection subjects affected / exposed occurrences (all) | 8 / 183 (4.37%) 19 | 9 / 177 (5.08%) 16 | 8 / 179 (4.47%) 14 |
| Respiratory tract infection subjects affected / exposed occurrences (all) | 6 / 183 (3.28%) 11 | 13 / 177 (7.34%) 31 | 6 / 179 (3.35%) 12 |
| Tinea versicolour subjects affected / exposed occurrences (all) | 2 / 183 (1.09%) 4 | 3 / 177 (1.69%) 6 | 9 / 179 (5.03%) 23 |
| Metabolism and nutrition disorders | | | |
| Dyslipidaemia subjects affected / exposed occurrences (all) | 34 / 183 (18.58%) 110 | 29 / 177 (16.38%) 69 | 41 / 179 (22.91%) 124 |
| Hyperkalaemia subjects affected / exposed occurrences (all) | 43 / 183 (23.50%) 81 | 47 / 177 (26.55%) 77 | 44 / 179 (24.58%) 90 |
| Hypokalaemia subjects affected / exposed occurrences (all) | 47 / 183 (25.68%) 104 | 40 / 177 (22.60%) 88 | 40 / 179 (22.35%) 102 |
| Hyperglycaemia subjects affected / exposed occurrences (all) | 35 / 183 (19.13%) 76 | 29 / 177 (16.38%) 81 | 37 / 179 (20.67%) 80 |
| Hypocalcaemia subjects affected / exposed occurrences (all) | 35 / 183 (19.13%) 61 | 37 / 177 (20.90%) 68 | 22 / 179 (12.29%) 43 |
| Hypophosphataemia subjects affected / exposed occurrences (all) | 35 / 183 (19.13%) 70 | 34 / 177 (19.21%) 60 | 22 / 179 (12.29%) 56 |
| Hypercholesterolaemia subjects affected / exposed occurrences (all) | 21 / 183 (11.48%) 76 | 20 / 177 (11.30%) 45 | 23 / 179 (12.85%) 61 |
| Hyperuricaemia | | | |

| | | | |
|-----------------------------|-------------------|-------------------|-------------------|
| subjects affected / exposed | 16 / 183 (8.74%) | 16 / 177 (9.04%) | 31 / 179 (17.32%) |
| occurrences (all) | 30 | 58 | 73 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 24 / 183 (13.11%) | 16 / 177 (9.04%) | 22 / 179 (12.29%) |
| occurrences (all) | 45 | 27 | 49 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 21 / 183 (11.48%) | 14 / 177 (7.91%) | 26 / 179 (14.53%) |
| occurrences (all) | 44 | 20 | 52 |
| Diabetes mellitus | | | |
| subjects affected / exposed | 14 / 183 (7.65%) | 18 / 177 (10.17%) | 19 / 179 (10.61%) |
| occurrences (all) | 27 | 35 | 38 |
| Decreased appetite | | | |
| subjects affected / exposed | 15 / 183 (8.20%) | 16 / 177 (9.04%) | 17 / 179 (9.50%) |
| occurrences (all) | 27 | 27 | 29 |
| Metabolic acidosis | | | |
| subjects affected / exposed | 15 / 183 (8.20%) | 16 / 177 (9.04%) | 16 / 179 (8.94%) |
| occurrences (all) | 21 | 32 | 25 |
| Hyperphosphataemia | | | |
| subjects affected / exposed | 16 / 183 (8.74%) | 15 / 177 (8.47%) | 15 / 179 (8.38%) |
| occurrences (all) | 32 | 25 | 29 |
| Acidosis | | | |
| subjects affected / exposed | 16 / 183 (8.74%) | 14 / 177 (7.91%) | 15 / 179 (8.38%) |
| occurrences (all) | 33 | 37 | 25 |
| Hyponatraemia | | | |
| subjects affected / exposed | 15 / 183 (8.20%) | 13 / 177 (7.34%) | 12 / 179 (6.70%) |
| occurrences (all) | 29 | 24 | 21 |
| Hyperlipidaemia | | | |
| subjects affected / exposed | 13 / 183 (7.10%) | 13 / 177 (7.34%) | 13 / 179 (7.26%) |
| occurrences (all) | 31 | 20 | 21 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 10 / 183 (5.46%) | 12 / 177 (6.78%) | 13 / 179 (7.26%) |
| occurrences (all) | 13 | 26 | 30 |
| Gout | | | |
| subjects affected / exposed | 3 / 183 (1.64%) | 11 / 177 (6.21%) | 7 / 179 (3.91%) |
| occurrences (all) | 6 | 38 | 10 |
| Dehydration | | | |

| | | | |
|-----------------------------|------------------|------------------|------------------|
| subjects affected / exposed | 13 / 183 (7.10%) | 10 / 177 (5.65%) | 8 / 179 (4.47%) |
| occurrences (all) | 18 | 17 | 12 |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 1 / 183 (0.55%) | 5 / 177 (2.82%) | 16 / 179 (8.94%) |
| occurrences (all) | 4 | 8 | 41 |
| Fluid overload | | | |
| subjects affected / exposed | 11 / 183 (6.01%) | 5 / 177 (2.82%) | 5 / 179 (2.79%) |
| occurrences (all) | 14 | 9 | 8 |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|------------------|--|
| 02 February 2005 | Post-transplant steroid tapering schedule was included, exclusion criteria for tuberculosis and mammogram requirements was modified. |
| 16 February 2006 | Month 24 Glomerular Filtration Rate (GFR) test and sample collection for Angiotensin II Type I (AT-1) receptor antibodies was added, administration of the first belatacept infusion on call to the operating room was permitted. Withholding only the morning dose Cyclosporine A prior to the GFR test Safety monitoring was initiated upon randomization prior to transplant. |
| 29 October 2007 | Long-term extension phase, extending the study two years was added, in-line filter manufacturer and specification details were added, serious adverse events reporting contact information and mailing addresses were updated. |
| 13 February 2009 | Surveillance measures for post-transplant lymphoproliferative disorder, safety data from the phase 3 studies, revised risk/benefit assessment, serious breach definition and reporting requirements were added. AT-1 receptor antibody sample collection and ICON Medical Monitor were removed. |
| 18 October 2010 | Added immunogenicity assessments after discontinuation. |
| 10 February 2011 | Updated benefit/risk assessment, added procedures to monitor and better understand post-transplant lymphoproliferative disorder (PTLD) and progressive multifocal leukoencephalopathy (PML), added monitoring guidelines for drug induced liver toxicity (DILI). |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported